<SEC-DOCUMENT>0001493152-25-017446.txt : 20251008
<SEC-HEADER>0001493152-25-017446.hdr.sgml : 20251008
<ACCEPTANCE-DATETIME>20251008171043
ACCESSION NUMBER:		0001493152-25-017446
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		21
CONFORMED PERIOD OF REPORT:	20251006
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251008
DATE AS OF CHANGE:		20251008

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioRestorative Therapies, Inc.
		CENTRAL INDEX KEY:			0001505497
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				301341024
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37603
		FILM NUMBER:		251383077

	BUSINESS ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747
		BUSINESS PHONE:		(631) 760-8100

	MAIL ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stem Cell Assurance, Inc.
		DATE OF NAME CHANGE:	20101110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:BRTX="http://biorestorativetherapiesinc.com/20251006">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_BRTX_biorestorativetherapiesinc.com_20251006 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20251006_20251006 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001505497 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000004" name="dei:EntityCentralIndexKey">0001505497</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="brtx-20251006.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-10-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-06</xbrli:startDate>
        <xbrli:endDate>2025-10-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_902_edei--DocumentType_c20251006__20251006_z96Eret6eP64"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 13 or 15(d) of the</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
Exchange Act of 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report: <span id="xdx_90A_edei--DocumentPeriodEndDate_c20251006__20251006_zivrtCFiK9O4"><ix:nonNumeric contextRef="AsOf2025-10-06" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">October 6, 2025</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Date
of earliest event reported)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="xdx_90F_edei--EntityRegistrantName_c20251006__20251006_zQjoxMhfa0He" style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><span style="text-decoration: underline"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000011" name="dei:EntityRegistrantName">BIORESTORATIVE
THERAPIES, INC.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20251006__20251006_z4JNdVnPMe65"><ix:nonNumeric contextRef="AsOf2025-10-06" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></td>
    <td style="padding-bottom: 1pt; text-align: center; font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--EntityFileNumber_c20251006__20251006_zqet2RR7vzH3"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000013" name="dei:EntityFileNumber">001-37603</ix:nonNumeric></span></span></td>
    <td style="padding-bottom: 1pt; text-align: center; font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20251006__20251006_zNNUcXSMZJue"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000014" name="dei:EntityTaxIdentificationNumber">30-1341024</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or Other Jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    Incorporation)</span></p></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    File No.)</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
                                            Employer</span></p>
                                                                             <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
                                                                             Number)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--EntityAddressAddressLine1_c20251006__20251006_zoWR0xCF0g48"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000015" name="dei:EntityAddressAddressLine1">40
    Marcus Drive</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressCityOrTown_c20251006__20251006_zK3DnhETPRYf"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000016" name="dei:EntityAddressCityOrTown">Melville</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20251006__20251006_zTyuoTFSAOF8"><ix:nonNumeric contextRef="AsOf2025-10-06" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric> </span></span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--EntityAddressPostalZipCode_c20251006__20251006_zZfPQsf0bsjj"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000018" name="dei:EntityAddressPostalZipCode">11747</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of Principal Executive Offices)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code: <span style="text-decoration: underline"><span id="xdx_909_edei--CityAreaCode_c20251006__20251006_zk4rXRWlPpb6"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000019" name="dei:CityAreaCode">(631)</ix:nonNumeric></span> <span id="xdx_909_edei--LocalPhoneNumber_c20251006__20251006_zrMidqY0Wxqk"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000020" name="dei:LocalPhoneNumber">760-8100</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_edei--WrittenCommunications_c20251006__20251006_zEjYAr7C29p1"><ix:nonNumeric contextRef="AsOf2025-10-06" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
                                            communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_edei--SolicitingMaterial_c20251006__20251006_zjRSATstMAK2"><ix:nonNumeric contextRef="AsOf2025-10-06" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
                                            material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_edei--PreCommencementTenderOffer_c20251006__20251006_zzV4SpZp0f3c"><ix:nonNumeric contextRef="AsOf2025-10-06" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
                                            communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20251006__20251006_zDgOTF8ZewS7"><ix:nonNumeric contextRef="AsOf2025-10-06" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
                                            of each class</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"/>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
                                            Symbol(s)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"/>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--Security12bTitle_c20251006__20251006_zEnbhpgJCgwa"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000025" name="dei:Security12bTitle">Common
    Stock, $0.0001 par value</ix:nonNumeric></span></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20251006__20251006_zkkRplx8yqnh"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000026" name="dei:TradingSymbol">BRTX</ix:nonNumeric></span></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--SecurityExchangeName_c20251006__20251006_zHqfGoumoXeg"><ix:nonNumeric contextRef="AsOf2025-10-06" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20251006__20251006_zrHmJeHPr7R2"><ix:nonNumeric contextRef="AsOf2025-10-06" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry
    into a Material Definitive Agreement.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subscription
Agreements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 6, 2025, BioRestorative Therapies, Inc. (the &#8220;Company&#8221;) entered into subscription agreements (the &#8220;Subscription
Agreements&#8221;) with several investors (the &#8220;Purchasers&#8221;) pursuant to which the Company agreed to sell and issue to the
Purchasers an aggregate of 678,125 shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Shares&#8221;),
in a registered direct offering at an offering price of $1.60 per share (the &#8220;Registered Offering&#8221;). Pursuant to the Subscription
Agreements, in a concurrent private placement offering (the &#8220;Private Placement&#8221;), the Company agreed to issue to the Purchasers
unregistered warrants (the &#8220;Unregistered Warrants&#8221;) to purchase up to an aggregate of 508,592 shares of the Company&#8217;s
common stock (the &#8220;Unregistered Warrant Shares&#8221;) at an exercise price of $2.75 per share. The Registered Offering and the
Private Placement are expected to close on or about October 8, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gross proceeds of the offering will be $1.085 million, before deducting placement agent fees and expenses and offering expenses payable
by the Company and excluding the proceeds of any exercise of the Unregistered Warrants. The Company intends to use the net proceeds from
the offering in connection with its clinical trials with respect to its lead cell therapy candidate, <i>BRTX-100</i>, pre-clinical research
and development with respect to its metabolic <i>ThermoStem Program, </i>the development of its commercial biocosmeceuticals platform
and for general corporate purposes and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shares are being offered pursuant to the Company&#8217;s effective registration statement on Form S-3 and accompanying base prospectus
(File No. 333-269631), previously filed with and declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;)
and a prospectus supplement, dated October 6, 2025, filed with the SEC on October 8, 2025 pursuant to Rule 424(b)(5) under the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the offering, the Company entered into an engagement letter, dated August 11, 2025 (the &#8220;Engagement letter&#8221;),
with Alere Financial Partners (a division of Cova Capital Partners, LLC) (the &#8220;Placement Agent&#8221;), pursuant to which the Company
agreed to pay the Placement Agent a cash fee equal to 6% of the gross proceeds of the offering from investors introduced to the Company
by the Placement Agent (the &#8220;Placement Agent Investors&#8221;) (4% for other investors). The Company has also agreed to reimburse
the Placement Agent approximately $8,300 for out-of-pocket expenses for legal fees and other expenses. In addition, the Company agreed
to issue to the Placement Agent, at the closing of the offering, a warrant exercisable commencing six months from the date of issuance
until the five year anniversary of the date of issuance to purchase up to 6% of the number of Shares sold in the Registered Offering
to Placement Agent Investors (4% for other investors), at a per share exercise price of $2.75.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing descriptions of the Subscription Agreements and the Engagement Letter are not complete and are qualified in their entirety
by reference to the full texts of the form of Subscription Agreement and the Engagement Letter, copies of which are filed as Exhibits
10.1 and 10.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the legal opinion of Certilman Balin Adler &amp; Hyman, LLP, counsel to the Company, relating to the legality of the issuance
and sale of the Shares in the Registered Offering is attached as Exhibit 5.1 to this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Unregistered
Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Unregistered Warrant sold in the Private Placement will be exercisable commencing six months from the date of issuance until the five
year anniversary of the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
at the time a holder exercises its Unregistered Warrant, a registration statement covering the resale of the Unregistered Warrant Shares
under the Securities Act is not in effect, then, in lieu of making the cash payment otherwise contemplated to be made to the Company
upon such exercise in payment of the aggregate exercise price, the holder may elect instead to make a cashless exercise of the Unregistered
Warrants and receive upon such exercise the net number of shares of the Company&#8217;s common stock determined according to a formula
set forth in the Unregistered Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder will not have the right to exercise its portion of any Unregistered Warrant if, upon giving effect to such exercise, the aggregate
number of shares of the Company&#8217;s common stock beneficially owned by the holder (together with its affiliates) would exceed 4.99%
of the number of shares of common stock of the Company outstanding immediately after giving effect to the exercise, subject to adjustment
as provided for in such warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
certain circumstances, in the event of a fundamental transaction (as described in the Unregistered Warrants), the holders of Unregistered
Warrants will be entitled to receive, upon exercise of the Unregistered Warrants, the kind and amount of securities or other consideration
that the holders would have received had they exercised the Unregistered Warrants immediately prior to such fundamental transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the last reported sale price of the Company&#8217;s common stock is greater than $5.00 per share for any ten consecutive trading days,
the Company may redeem each holder&#8217;s Unregistered Warrants for an aggregate redemption price of $1.00 upon at least 30 days prior
written notice of the redemption date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the Unregistered Warrants is not complete and is qualified in its entirety by reference to the full text of
the form of Unregistered Warrant, a copy of which is filed as Exhibit 4.1 to this Current Report on Form 8-K and is incorporated by reference
herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    3.02.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unregistered
    Sales of Equity Securities.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth above in Item 1.01 with regard to the Private Placement is hereby incorporated by reference into this Item 3.02.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
in part upon the representations of the investors in the Subscription Agreements, the offering and sale of the Unregistered Warrants
and the Unregistered Warrant Shares in the Private Placement is being conducted pursuant to an exemption from the registration requirements
of the Securities Act provided for in Section 4(a)(2) of the Securities Act and/or Rule 506(b) promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Unregistered Warrants and the Unregistered Warrant Shares have not been registered under the Securities Act or any state securities laws,
and the Unregistered Warrants and Unregistered Warrant Shares may not be offered or sold absent registration with the SEC or an applicable
exemption from the registration requirements. The Private Placement will not involve a public offering and will be made without general
solicitation or general advertising. Each Purchaser represented that it is an &#8220;accredited investor&#8221;, as defined in Rule 501(a)
under the Securities Act, or a &#8220;qualified institutional buyer&#8221;, as defined in Rule 144A under the Securities Act, and that
it is acquiring the Unregistered Warrants for investment purposes only and not with a view to any resale, distribution or other disposition
of the Unregistered Warrants in violation of the United States federal securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    7.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation
    FD Disclosure.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
October 6, 2025, the Company issued a press release regarding the pricing of the Registered Offering (the &#8220;Press Release&#8221;).
A copy of the Press Release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information referenced under this Item 7.01 (including Exhibit 99.1 referenced in Item 9.01 below) of this Current Report on Form 8-K
is being &#8220;furnished&#8221; under this Item 7.01 and, as such, shall not be deemed to be &#8220;filed&#8221; for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information
set forth in this Current Report on Form 8-K with respect to the Press Release shall not be incorporated by reference into any registration
statement, report or other document filed by the Company pursuant to the Securities Act, except as shall be expressly set forth by specific
reference in such filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    Statements and Exhibits.</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Exhibits</span></span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Form
    of Unregistered Warrant.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Opinion
    of Certilman Balin Adler &amp; Hyman, LLP.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Form
    of Subscription Agreement, dated October 6, 2025, by and between the Company and the Purchasers.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-2.htm">Engagement
    Letter, dated August 11, 2025, by and between the Company and the Placement Agent.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press
    release of the Company, dated October 6, 2025.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIORESTORATIVE
    THERAPIES, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    October 8, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/Lance
    Alstodt</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer </span></td></tr>
  </table>

<p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6La4bqLBLxxRxyhhDvK0uSnFrRlr/Hsm3tNsQQyAk53wnQkzEmla6QYbjssyhwrZrlEMo8YKM5ozekW62CfhZ4lVbx8q4Yf2BKXkGPTOfRid/H5wPbbFOIJKhXITxDOQ8iSQUOxH0ekrmoms0TqsGlKmhYOpYo1P8HhMq9SJD7Xv4dEC2moyPm8pR/kAsoxj29FBP4puFPE9FMBkqEGume+dd2cuh6UnIGmz9OzvS/w6+yGVKVw== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR
TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON
EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMMON
STOCK PURCHASE WARRANT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
THERAPIES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
Shares: [_______________]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Issuance: October 8, 2025 (&ldquo;<U>Issuance Date</U>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, [______] (including any permitted
and registered assigns, the &ldquo;<U>Holder</U>&rdquo;), is entitled, upon the terms and subject to the limitations on exercise and
the conditions hereinafter set forth, at any time on or after the date of issuance hereof, to purchase from BioRestorative Therapies,
Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), [________] shares of Common Stock (the &ldquo;<U>Warrant Shares</U>&rdquo;)
(whereby such number may be adjusted from time to time pursuant to the terms and conditions of this Warrant) at the Exercise Price per
share then in effect during the Exercise Period (defined below). This Warrant is issued by the Company as of the date hereof in connection
with that certain Subscription Agreement, dated October 6, 2025, by and between the Company and the Holder (the &ldquo;<U>Subscription
Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized
terms used in this Warrant shall have the meanings set forth in the Subscription Agreement unless otherwise defined in the body of this
Warrant or in Section 13 below. For purposes of this Warrant, the term &ldquo;Exercise Price&rdquo; shall mean $2.75 per share, subject
to adjustment as provided herein, and the term &ldquo;Exercise Period&rdquo; shall mean the period commencing six (6) months following
the Issuance Date and ending at 5:00 p.m. eastern standard time on the five (5) year anniversary thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>EXERCISE OF WARRANT</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<I>Mechanics of Exercise</I>. Subject to the terms and conditions hereof, the rights represented by this Warrant may be exercised in
whole or in part at any time or times during the Exercise Period by delivery of a written notice, in the form attached hereto as <U>Exhibit
A</U> (the &ldquo;<U>Exercise Notice</U>&rdquo;), of the Holder&rsquo;s election to exercise this Warrant. The Holder shall not be required
to deliver the original Warrant in order to effect an exercise hereunder; provided, however, if this Warrant has been exercised in full,
the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final
Exercise Notice is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number
of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder
in an amount equal to the applicable number of Warrant Shares purchased. On or before the second Trading Day (the &ldquo;<U>Warrant Share
Delivery Date</U>&rdquo;) following the date on which the Holder&rsquo;s Exercise Notice is received by the Company or the Company&rsquo;s
transfer agent, and upon receipt by the Company of payment to the Company of an amount equal to the applicable Exercise Price multiplied
by the number of Warrant Shares as to which all or a portion of this Warrant is being exercised (the &ldquo;<U>Aggregate Exercise Price</U>&rdquo;
and together with the Exercise Notice, the &ldquo;<U>Exercise Delivery Documents</U>&rdquo;) in cash or by wire transfer of immediately
available funds (or by cashless exercise, as provided for herein, in which case no cash payment shall be provided), the Company shall
(or direct its transfer agent to) issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate,
registered in the Company&rsquo;s share register in the name of the Holder or, subject to the provisions of applicable law, its designee,
for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise (or deliver such shares of Common
Stock in electronic format). Upon delivery of the Exercise Delivery Documents, the Holder shall be deemed for all corporate purposes
to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the
date of delivery of the certificates evidencing such Warrant Shares. If this Warrant is submitted in connection with any exercise and
the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired
upon an exercise, then, at the written request of the Holder, the Company shall as soon as practicable and in no event later than three
Trading Days after any such exercise and request and at its own expense, issue a new Warrant (in accordance with Section 7) representing
the right to purchase the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant, less the number
of Warrant Shares with respect to which this Warrant is exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company fails to cause its transfer agent to transmit to the Holder the respective shares of Common Stock by the respective Warrant
Share Delivery Date, then the Holder will have the right, but not the obligation, to rescind such exercise in Holder&rsquo;s sole discretion
in addition to all other rights and remedies at law, under this Warrant, or otherwise, and such failure shall also be deemed a material
breach under this Warrant, and a material breach under the Subscription Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
at the time an Exercise Notice is delivered, the Market Price of one share of Common Stock is greater than the Exercise Price, then,
unless there is an effective registration statement of the Company covering the resale of the Holder&rsquo;s Warrant Shares, the Holder
may elect to receive Warrant Shares pursuant to a cashless exercise, in lieu of a cash exercise, equal to the value of this Warrant determined
in the manner described below (or of any portion thereof remaining unexercised) by surrender of this Warrant and a Notice of Exercise,
in which event the Company shall issue to the Holder a number of shares of Common Stock computed using the following formula:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">X = <U>Y (A-B)</U></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Where</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">X =</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
        number of Shares to be issued to the Holder.</FONT></TD></TR>
                                                                                                                                      <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                                                                                                                      <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD>
    <TD STYLE="width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Y
                                        =</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number of Warrant Shares that the Holder elects to purchase under this Warrant (at the date
                                            of such calculation).</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                                                                  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">A =</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
      Market Price (at the date of such calculation).</FONT></TD></TR>
                                                                                  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                                                                  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B
                   =</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercise
      Price (as adjusted to the date of such calculation).</FONT></TD></TR>
                                                                                  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<I>No Fractional Shares</I>. No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment
pursuant hereto. All Warrant Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining
whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance
of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction
a sum in cash equal to the product resulting from multiplying the then-current fair market value of a Warrant Share by such fraction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<I>Holder&rsquo;s Exercise Limitations</I>. Notwithstanding anything to the contrary contained herein, the Company shall not effect any
exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 1 or otherwise,
to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder
(together with the Holder&rsquo;s affiliates (the &ldquo;Affiliates&rdquo;), and any other Persons acting as a group together with the
Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;Attribution Parties&rdquo;)), would beneficially own in excess of
the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock
beneficially owned by the Holder and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of
this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would
be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company
(including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the
limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in
the preceding sentence, for purposes of this Section 1(c), beneficial ownership shall be calculated in accordance with Section 13(d)
of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Holder is solely
responsible for any schedules required to be filed in accordance therewith. In addition, a determination as to any group status as contemplated
above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.
For purposes of this Section 1(c), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of
outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission,
as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Company&rsquo;s
transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of the Holder, the Company
shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any
case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities
of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number
of outstanding shares of Common Stock was reported. The &ldquo;Beneficial Ownership Limitation&rdquo; shall be 4.99% of the number of
shares of the Common Stock outstanding at the time of the respective calculation hereunder. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant. By written notice to the Company, the Holder may waive the provisions of this section
or increase or decrease the Beneficial Ownership Limitation to any other percentage specified in such notice, but (i) any such waiver
or increase will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company, and (ii) any such waiver
or increase or decrease will apply only to the Holder and not to any other holder of Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<I>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</I>. In addition to any other rights available to
the Holder, if the Company fails to cause the Company&rsquo;s transfer agent to transmit to the Holder the Warrant Shares in accordance
with the provisions of this Warrant (including but not limited to Section 1(a) above) pursuant to an exercise on or before the respective
Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or
otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the
Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;Buy-In&rdquo;), then the Company shall
(A) pay in cash to the Holder, within three (3) business days of Holder&rsquo;s request, the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the product of
(1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times
(2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either
reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such
exercise shall be deemed rescinded) or deliver to the Holder within three (3) business days of Holder&rsquo;s request the number of shares
of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For
example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted
exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)
of the immediately preceding sentence, the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written
notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount
of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in
equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure
to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>REDEMPTION</U>. Subject to the provisions of this Section 2, at any time after the date hereof, if the last reported sale price of
the Common Stock on the principal stock exchange or quotation service on which the Common Stock trades is greater than $5.00 (subject
to adjustment pursuant to Section 3 hereof) for any ten (10) consecutive trading days, the Company may redeem this Warrant at an aggregate
price of $1.00 (the &ldquo;<U>Redemption Price</U>&rdquo;). To exercise this right, the Company shall, not less than thirty (30) days
prior to the Redemption Date (as defined below), deliver to the Holder an irrevocable written notice (the &ldquo;<U>Redemption Notice</U>&rdquo;)
informing the Holder that the Common Stock has traded at the required levels for the specified time period and specifying the date on
which the Company shall redeem this Warrant in accordance with this Section 2 (the &ldquo;<U>Redemption Date</U>&rdquo;). To the extent
this Warrant is not exercised by the Holder on or before the Redemption Date, then this Warrant shall be cancelled at 5:00 p.m., Eastern
Time, on the Redemption Date, and the Company shall thereafter deliver the Redemption Price to the Holder at its address of record. The
Company covenants and agrees that it will honor all notices of exercise with respect to the Warrant Shares that are delivered by the
Holder in accordance with Section 1 and received by the Company from the time of delivery of the Redemption Notice through 5:00 p.m.,
Eastern Time, on the Redemption Date. For the avoidance of doubt, the Company&rsquo;s delivery to the Holder of the Redemption Price
of $1.00 in total shall be effective to redeem this Warrant in its entirety pursuant to this Section 2 without regard to the number of
shares of Common Stock then potentially issuable upon exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>ADJUSTMENTS</U>. The Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<I>Distribution of Assets</I>. If the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire
its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including without limitation any distribution
of cash (other than ordinary course cash dividends), stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant
within the Exercise Period, then, in each such case:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
any Exercise Price in effect immediately prior to the close of business on the record date fixed for the determination of holders of
shares of Common Stock entitled to receive the Distribution shall be reduced, effective as of the close of business on such record date,
to a price determined by multiplying such Exercise Price by a fraction (i) the numerator of which shall be the Closing Sale Price of
the shares of Common Stock on the Trading Day immediately preceding such record date minus the value of the Distribution (as determined
in good faith by the Company&rsquo;s Board of Directors) applicable to one share of Common Stock, and (ii) the denominator of which shall
be the Closing Sale Price of the shares of Common Stock on the Trading Day immediately preceding such record date; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
the number of Warrant Shares shall be increased to a number of shares equal to the number of shares of Common Stock obtainable immediately
prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock entitled to receive
the Distribution multiplied by the reciprocal of the fraction set forth in the immediately preceding clause (i).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<I>Subdivision or Combination of Common Stock</I>. If the Company at any time on or after the Issuance Date subdivides (by any stock
split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number
of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant
Shares will be proportionately increased. If the Company at any time on or after the Issuance Date combines (by combination, reverse
stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Exercise
Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares will be proportionately
decreased. Any adjustment under this Section 3(b) shall become effective at the close of business on the date the subdivision or combination
becomes effective. Each such adjustment of the Exercise Price shall be calculated to the nearest one-hundredth of a cent. Such adjustment
shall be made successively whenever any event covered by this Section 3(b) shall occur.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>FUNDAMENTAL TRANSACTIONS</U>. If, at any time while this Warrant is outstanding, (i) the Company effects any merger of the Company
with or into another entity and the Company is not the surviving entity (such surviving entity, the &ldquo;<U>Successor Entity</U>&rdquo;),
(ii) the Company effects any sale of all or substantially all of its assets in one or a series of related transactions, (iii) any tender
offer or exchange offer (whether by the Company or by another individual or entity, and approved by the Company) is completed pursuant
to which holders of Common Stock are permitted to tender or exchange their shares of Common Stock for other securities, cash or property
and the holders of at least 50% of the combined voting power of all classes of the Company&rsquo;s stock accept such offer, or (iv) the
Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares
of Common Stock) (in any such case, a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant,
the Holder shall have the right to receive the number of shares of Common Stock of the Successor Entity or of the Company and any additional
consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable upon or as a result of such reorganization, reclassification,
merger, consolidation or disposition of assets by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such event (disregarding any limitation on exercise contained herein solely for the purpose of such determination).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. To the extent necessary to effectuate the foregoing
provisions, any Successor Entity in such Fundamental Transaction shall issue to the Holder a new warrant consistent with the foregoing
provisions and evidencing the Holder&rsquo;s right to exercise such warrant into Alternate Consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>NON-CIRCUMVENTION</U>. The Company covenants and agrees that it will not, by amendment of its certificate of incorporation, bylaws
or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities,
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at
all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect the rights of
the Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common
Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take all such actions as may be
necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable shares of Common Stock
upon the exercise of this Warrant, and (iii) shall, for so long as this Warrant is outstanding, have authorized and reserved, free from
preemptive rights, the number of shares of Common Stock into which the Warrants are then exercisable to provide for the exercise of the
rights represented by this Warrant (without regard to any limitations on exercise).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>WARRANT HOLDER NOT DEEMED A STOCKHOLDER</U>. Except as otherwise specifically provided herein, this Warrant, in and of itself, shall
not entitle the Holder to any voting rights or other rights as a stockholder of the Company. In addition, nothing contained in this Warrant
shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise)
or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>REISSUANCE</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<I>Lost, Stolen or Mutilated Warrant</I>. If this Warrant is lost, stolen, mutilated or destroyed, the Company will, on such terms as
to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof),
issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<I>Issuance of New Warrants</I>. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such
new Warrant shall be of like tenor with this Warrant, and shall have an issuance date, as indicated on the face of such new Warrant which
is the same as the Issuance Date.</FONT></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>TRANSFER</U>. This Warrant shall be binding upon the Company and its successors and assigns, and shall inure to be the benefit of
the Holder and its successors and assigns. Notwithstanding anything to the contrary herein, the rights, interests or obligations of the
Company hereunder may not be assigned, by operation of law or otherwise, in whole or in part, by the Company without the prior signed
written consent of the Holder, which consent may be withheld at the sole discretion of the Holder (any such assignment or transfer shall
be null and void if the Company does not obtain the prior signed written consent of the Holder). This Warrant or any of the severable
rights and obligations inuring to the benefit of or to be performed by Holder hereunder may be assigned by Holder to a third party, in
whole or in part, without the need to obtain the Company&rsquo;s consent thereto, but subject to the provisions of applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>NOTICES</U>. Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given
in accordance with the notice provisions contained in the Subscription Agreement. The Company shall provide the Holder with prompt written
notice (i) immediately upon any adjustment of the Exercise Price, setting forth in reasonable detail, the calculation of such adjustment
and (ii) at least 20 days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend
or distribution upon the shares of Common Stock (other than ordinary course cash dividends), (B) with respect to any grants, issuances
or sales of any stock or other securities directly or indirectly convertible into or exercisable or exchangeable for shares of Common
Stock or other property, pro rata to the holders of shares of Common Stock or (C) for determining rights to vote with respect to any
Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior
to or in conjunction with such notice being provided to the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<U>AMENDMENT AND WAIVER</U>. The terms of this Warrant may be amended or waived (either generally or in a particular instance and either
retroactively or prospectively) only with the written consent of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>GOVERNING LAW AND VENUE; ATTORNEYS FEES; SEVERABLITY; SERVICE OF PROCESS</U>. This Warrant shall be governed by and construed in accordance
with the laws of the State of Nevada without regard to principles of conflicts of laws. Any action brought by either party against the
other concerning the transactions contemplated by this Warrant shall be brought only in the state courts located in the State of New
York or federal courts located in the State of New York. The parties to this Warrant hereby irrevocably waive any objection to jurisdiction
and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon <I>forum
non conveniens</I>. <B>EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE
ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT ENTERED INTO IN CONNECTION WITH OR ARISING OUT OF THIS
WARRANT, OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY</B>. The prevailing party shall be entitled to recover from the other party
its reasonable attorney&rsquo;s fees and costs. In the event that any provision of this Warrant or any other agreement delivered in connection
herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to
the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision
which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any
agreement. Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action
or proceeding in connection with this Warrant or any other transaction document entered into in connection with this Warrant by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under the Subscription Agreement and agrees that such service shall constitute good and sufficient service of process
and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<U>ACCEPTANCE</U>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions
contained herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<U>CERTAIN DEFINITIONS</U>. For purposes of this Warrant, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&ldquo;<U>Nasdaq</U>&rdquo; means <U>www.Nasdaq.com.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
&ldquo;<U>Closing Sale Price</U>&rdquo; means, for any security as of any date, (i) the last closing trade price for such security on
the Principal Market, as reported by Nasdaq, or, if the Principal Market begins to operate on an extended hours basis and does not designate
the closing trade price, then the last trade price of such security prior to 4:00 p.m., New York time, as reported by Nasdaq, or (ii)
if the foregoing does not apply, the last trade price of such security in the over-the-counter market for such security as reported by
Nasdaq, or (iii) if no last trade price is reported for such security by Nasdaq, the average of the bid and ask prices of any market
makers for such security as reported by the OTC Markets. If the Closing Sale Price cannot be calculated for a security on a particular
date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined
by the Company and the Holder. All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination
or other similar transaction during the applicable calculation period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
&ldquo;<U>Common Stock</U>&rdquo; means the Company&rsquo;s common stock, par value $0.0001, and any other class of securities into which
such securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
&ldquo;<U>Common Stock Equivalents</U>&rdquo; means any securities of the Company that would entitle the holder thereof to acquire at
any time Common Stock, including without limitation any debt, preferred stock, rights, options, warrants or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
&ldquo;<U>Person</U>&rdquo; and &ldquo;<U>Persons</U>&rdquo; means an individual, a limited liability company, a partnership, a joint
venture, a corporation, a trust, an unincorporated organization, any other entity and any governmental entity or any department or agency
thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
&ldquo;<U>Principal Market</U>&rdquo; means the principal securities exchange or trading market where such Common Stock is listed or
quoted, including but not limited to any tier of the OTC Markets, any tier of the NASDAQ Stock Market (including NASDAQ Capital Market),
or the NYSE American, or any successor to such markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
&ldquo;<U>Market Price</U>&rdquo; means the Closing Sale Price of the Common Stock on the Trading Day immediately prior to the date of
the Exercise Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
&ldquo;<U>Trading Day</U>&rdquo; means any day on which the Common Stock is listed or quoted on its Principal Market, provided, however,
that if the Common Stock is not then listed or quoted on any Principal Market, then any calendar day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
* * * * * *</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Common Stock Purchase Warrant to be duly executed as of the Issuance Date set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD COLSPAN="2"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIORESTORATIVE
                  THERAPIES, INC.</FONT></P>

 &nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Lance Alstodt</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>EXHIBIT
A</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXERCISE
NOTICE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(To
be executed by the registered holder to exercise this Common Stock Purchase Warrant)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
UNDERSIGNED holder (the &ldquo;Holder&rdquo;) hereby exercises the right to purchase _______________________ of the shares of Common
Stock (&ldquo;Warrant Shares&rdquo;) of BIORESTORATIVE THERAPIES, INC., a Nevada corporation (the &ldquo;Company&rdquo;), evidenced by
the attached copy of the Common Stock Purchase Warrant (the &ldquo;Warrant&rdquo;). Capitalized terms used herein and not otherwise defined
shall have the respective meanings set forth in the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Form
                                            of Exercise Price</U>. The Holder desires that payment of the Exercise Price shall be made
                                            as (check one):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            cash exercise with respect to the Warrant Shares; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            cashless exercise pursuant to the provisions of the Warrant.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Payment
                                            of Exercise Price</U>. If a cash exercise, the Holder shall pay the applicable Aggregate
                                            Exercise Price in the sum of $____________ to the Company in accordance with the terms of
                                            the Warrant.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delivery
                                            of Warrant Shares</U>. The Company shall deliver to the Holder the Warrant Shares in accordance
                                            with the terms of the Warrant.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print
  Name of Registered Holder)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>EXHIBIT B</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSIGNMENT
OF WARRANT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(To
be signed only upon authorized transfer of the Warrant)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the undersigned hereby sells, assigns, and transfers unto __________________ the right to purchase ________________ shares
of common stock of BIORESTORATIVE THERAPIES, INC., to which the within Common Stock Purchase Warrant relates and appoints ___________________________,
as attorney-in-fact, to transfer said right on the books of BIORESTORATIVE THERAPIES, INC. with full power of substitution and re-substitution
in the premises. By accepting such transfer, the transferee has agreed to be bound in all respects by the terms and conditions of the
within Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature) *</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name)</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address)</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Social Security or Tax Identification No.)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
The signature on this Assignment of Warrant must correspond to the name as written upon the face of the Common Stock Purchase Warrant
in every particular without alteration or enlargement or any change whatsoever. When signing on behalf of a corporation, partnership,
trust or other entity, please indicate your position(s) and title(s) with such entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex5-1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT="" style="width:720px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Fred
S. Skolnik</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Partner</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Direct
Dial</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">516.296.7048</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fskolnik@certilmanbalin.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
6, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
Therapies, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40
Marcus Drive</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
One</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melville,
New York 11747</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to BioRestorative Therapies, Inc., a Nevada corporation (the &ldquo;Company&rdquo;), in connection with the Registration
Statement on Form S-3 (File No. 333-269631) (the &ldquo;Registration Statement&rdquo;) filed with the Securities and Exchange Commission
(the &ldquo;Commission&rdquo;) pursuant to the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and the rules and
regulations thereunder (the &ldquo;Rules&rdquo;), which became effective on February 14, 2023. You have asked us to furnish our opinion
as to the legality of the 678,125 shares of common stock of the Company, par value $0.0001 per share (the &ldquo;Shares&rdquo;), which
are registered under the Registration Statement and which are to be issued and sold by the Company pursuant to the Subscription Agreements,
dated as of October 6, 2025, by and between the Company and the purchasers signatory thereto (the &ldquo;Subscription Agreements&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the furnishing of this opinion, we have examined originals, or copies certified or otherwise identified to our satisfaction,
of the following documents:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Registration Statement;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
prospectus supplement dated October 6, 2025 (the &ldquo;Prospectus&rdquo;); and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Subscription Agreements.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have examined (i) such corporate records of the Company as we have considered appropriate, including a copy of the amended
and restated articles of incorporation and by-laws of the Company and copies of resolutions of the board of directors of the Company
relating to the issuance of the Shares, and (ii) such other certificates, agreements and documents as we deemed relevant and necessary
as a basis for the opinions expressed below. We have also relied upon the factual matters contained in the representations and warranties
of the Company made in the documents reviewed by us and upon certificates of public officials and the officers of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_002.jpg" ALT="" style="width:250px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_003.jpg" ALT="" style="width:230px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 6, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our examination of the documents referred to above, we have assumed, without independent investigation, the genuineness of all signatures,
the legal capacity of all individuals who have executed any of the documents reviewed by us, the authenticity of all documents submitted
to us as originals, the conformity to the originals of all documents submitted to us as certified, photostatic, reproduced or conformed
copies of valid existing agreements or other documents, the authenticity of all such latter documents and that the statements regarding
matters of fact in the certificates, records, agreements, instruments and documents that we have examined are accurate and complete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the above, and subject to the stated assumptions, exceptions and qualifications, we are of the opinion that the Shares have been
duly authorized by all necessary corporate action on the part of the Company and, when issued, delivered and paid for as contemplated
in the Registration Statement and in accordance with the terms of the Subscription Agreements, the Shares will be validly issued, fully
paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinion expressed above is limited to the Nevada Revised Statutes. Our opinion is rendered only with respect to the laws, and the rules,
regulations and orders under those laws, that are currently in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the use of this opinion as an exhibit to the Company&rsquo;s Current Report on Form 8-K filed by the Company with the
Commission on the date hereof, and to the use of our name under the heading &ldquo;Legal Matters&rdquo; contained in the base prospectus
included in the Registration Statement and in the Prospectus Supplement. In giving this consent, we do not thereby admit that we come
within the category of persons whose consent is required by the Securities Act or the Rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 3%">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><B>CERTILMAN BALIN ADLER &amp; HYMAN, LLP</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
  <TD STYLE="padding-bottom: 1pt; text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 10pt; text-indent: -10pt">/s/ Fred Skolnik</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Fred
Skolnik, a member of the Firm</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_002.jpg" ALT="" style="width:250px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>ex10-1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSCRIPTION AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: ______________, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative Therapies, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40 Marcus Drive, Suite 1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melville,
New York 11747</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned (the &ldquo;<B>Investor</B>&rdquo;<B>) </B>hereby confirms its agreement with BioRestorative Therapies, Inc., a Nevada corporation
(the &ldquo;<B>Company</B>&rdquo;<B>), </B>as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            Subscription Agreement, including the Investor Information attached hereto as <B>Annex A
                                            </B>(collectively, this &ldquo;<B>Agreement</B>&rdquo;<B>), </B>is made as of the date set
                                            forth above between the Company and the Investor.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has authorized the sale and issuance to the Investor and certain other investors
                                            of up to an aggregate of $_______ of shares of Common Stock (as defined below) (the &ldquo;<B>Shares</B>&rdquo;<B>)
                                            </B>and a warrant to purchase shares of Common Stock in the form of a Common Stock Purchase
                                            Warrant attached hereto as <B>Annex B </B>(the &ldquo;<B>Warrant</B>&rdquo; and, together
                                            with the Shares, the &ldquo;<B>Securities</B>&rdquo;<B>)</B>. For the purposes of this Agreement,
                                            &ldquo;<B>Common Stock</B>&rdquo; means the common stock of the Company, par value $.0001
                                            per share.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            offering and sale of the Shares (the &ldquo;<B>Shares Offering</B>&rdquo;<B>) </B>are being
                                            made pursuant to (A) an effective Registration Statement on Form S-3 (File No. 333-269631)
                                            (the &ldquo;<B>Registration Statement</B>&rdquo;), including the prospectus contained therein
                                            (the &ldquo;<B>Base Prospectus</B>&rdquo;<B>), </B>filed by the Company with the Securities
                                            and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;<B>) </B>on February 7, 2023,
                                            and (B) a Prospectus Supplement (the &ldquo;<B>Prospectus Supplement</B>&rdquo; and together
                                            with the Base Prospectus, the &ldquo;<B>Prospectus</B>&rdquo;<B>) </B>containing certain
                                            supplemental information regarding the Shares and the terms of the Shares Offering and information
                                            that may be material to the Company and its securities that was delivered to the Investor
                                            and will be filed with the Commission. The Prospectus, together with the documents incorporated
                                            by reference therein, are collectively referred to herein as the &ldquo;<B>Disclosure Package.</B>&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the avoidance of doubt, neither the Registration Statement nor the Prospectus register the sale of the Warrant or the shares of Common
Stock issuable upon the exercise of the Warrant (the &ldquo;<B>Warrant Shares</B>&rdquo;<B>) </B>to the Investor. The Warrant and the
Warrant Shares are being offered and sold by the Company to the Investor pursuant to an exemption from the registration requirements
of Section 5 of the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;<B>), </B>contained in Section 4(a)(2)
thereof and/or Regulation D promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Investor represents that it has received (or otherwise had made available to it by the filing
                                            by the Company of an electronic version thereof with the Commission) the Disclosure Package,
                                            which includes pricing and other information regarding the Shares Offering, prior to or in
                                            connection with the receipt of this Agreement and is relying only on such information and
                                            documents in making its decision to purchase the Shares.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company and the Investor agree that the Investor will purchase from the Company and the Company
                                            will issue and sell to the Investor the number of Shares set forth on the signature page
                                            below for the aggregate purchase price set forth below on the signature page below, with
                                            the purchase price being paid via wire transfer or overnight mail pursuant to the instructions
                                            attached hereto on <B>Annex C.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of Shares sold and issued to the Investor shall be equal to the &ldquo;<B>Aggregate Allocated Dollar Subscription Amount</B>&rdquo;
(as set forth on the signature page hereto) divided by the &ldquo;<B>Per Share Purchase Price</B>&rdquo; (as set forth on the signature
page hereto). The number of Warrant Shares underlying the Warrant shall be equal to 75% of the Shares purchased by the Investor with
an exercise price equal to $2.75, subject to adjustment as described therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Investor hereby represents and warrants to the Company as of the date this Agreement was
                                            executed by the Investor the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Investor understands that the Warrant and the Warrant Shares are &ldquo;restricted securities&rdquo; and have not been registered
under the Securities Act or any applicable state securities law in reliance on the availability of an exemption from such registration
requirements and that, under such laws and applicable regulations, such securities may be resold without registration under the Securities
Act only in certain limited circumstances. The Investor is acquiring the Warrant for investment purposes only and not with a view to
any resale, distribution or other disposition in violation of the United States securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
At the time the Investor was offered the Shares and the Warrant, it was, and as of the date hereof it is, and on each date on which it
exercises the Warrant, it will be either: (i) an &ldquo;accredited investor&rdquo; as defined in Rule 501(a) under the Securities Act
or (ii) a &ldquo;qualified institutional buyer&rdquo; as defined in Rule 144A(a) under the Securities Act. Such investor is a sophisticated
investor, with sufficient knowledge and experience in investing in private equity transactions to properly evaluate the risks and merits
of its purchase of the Warrant and the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Investor, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial
matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated
the merits and risks of such investment. The Investor is able to bear the economic risk of an investment in the Shares and the Warrant
and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Investor did not learn of the investment in the Securities as a result of any general or public solicitation or general advertising,
or publicly disseminated advertisements or sales literature, including, without limitation, (i) any advertisement, article, notice or
other communication published in any newspaper, magazine, website, or similar media, or broadcast over television or radio, or (ii) any
seminar or meeting to which the Investor was invited by any of the foregoing means of communications. Prior to the date hereof, the Investor
had a substantive pre-existing relationship with Alere Financial Partners (a division of Cova Capital Partners, LLC), the placement agent
for the Shares Offering, and was not solicited by the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            Agreement will involve no obligation or commitment of any kind until this Agreement is accepted
                                            and countersigned by or on behalf of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company agrees to use commercially reasonable efforts to have the resale of the Warrant Shares
                                            registered under the Securities Act no later than six (6) months from the date hereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            notice or other communication given hereunder shall be deemed sufficient if in writing and
                                            hand delivered or sent by certified mail, return receipt requested, or by receipted overnight
                                            mail or courier to the address of each party set forth below. Notices shall be deemed to
                                            have been given on the date of hand delivery or when received or rejected when sent by certified
                                            mail, or overnight courier. Either party hereto may change such address by notice given to
                                            the other party hereto in accordance with this Section 9.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
Therapies, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40
Marcus Drive, Suite One</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melville,
NY 11747</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a copy to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certilman
Balin Adler &amp; Hyman, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90
Merrick Avenue, 9<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">East
Meadow, NY 11554</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Fred Skolnik, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Investor, at the address indicated on the signature page.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            Agreement, including <B>Annexes A</B>, <B>B and C</B>, constitutes the entire agreement of
                                            the parties to this Agreement and supersedes all prior written or oral and all contemporaneous
                                            oral agreements, understandings and negotiations with respect to the subject matter hereof.
                                            In this Agreement, the masculine, feminine and neuter genders and the singular and the plural
                                            include one another.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page Follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor&rsquo;s
Aggregate Allocation Requested Dollar Subscription Amount: </B>$___________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Allocation:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aggregate
Allocated Dollar Subscription Amount: </B>$___________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
Share Purchase Price: </B>$_____</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
of Shares of Being Purchased: </B>___________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
of Warrant Shares underlying the Warrant: </B>___________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>(NOTE:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(&ldquo;Number
of the Shares Being Purchased&rdquo; </I>is equal to the <I>&ldquo;Aggregate Allocated Dollar Subscription Amount&rdquo; </I>divided
by the <I>&ldquo;Per Share Purchase Price&rdquo; </I>and the <I>&ldquo;Number of Warrant Shares underlying the Warrant&rdquo; </I>is
equal to <B>75% </B>of the <I>&ldquo;Number of Shares Being Purchased&rdquo;)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
confirm that the foregoing correctly sets forth the agreement between us by signing in the space provided below for that purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">INVESTOR</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Address:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreed and Accepted</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIORESTORATIVE THERAPIES, INC.</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Lance Alstodt</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page to Subscription Agreement]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ANNEX
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
THERAPIES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INVESTOR
INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
provide us with the following information:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            exact name that your shares of Common Stock are to be registered in (name must match the
                                            originating bank account information):</FONT></TD>
    </TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
                                           <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
                                            Social Security Number or Tax Identification Number:</FONT></TD>
    </TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
                                           <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
                                            a completed, executed Form W-9. A blank copy of a Form W-9 has been provided.</FONT></TD>
    </TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ANNEX
B </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
THERAPIES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
OF COMMON STOCK PURCHASE WARRANT </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[attached]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ANNEX
C </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
THERAPIES, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WIRE
TRANSFER INSTRUCTIONS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OVERNIGHT
MAIL INSTRUCTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>ex10-2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 10.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>STRICTLY PRIVATE AND CONFIDENTIAL</U></B></FONT></TD>
  <TD STYLE="text-align: right; width: 50%"><B>August 11, 2025</B></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>BioRestorative
Therapies, Inc.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Lance Alstodt, Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">40
Marcus Drive, Suite One, Melville, New York 11747</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Lance:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
Therapies, Inc. (together with any present and future subsidiaries and affiliates of BioRestorative Therapies, Inc., the &ldquo;Company&rdquo;)
hereby retains Alere Financial Partners (a division of Cova Capital Partners, LLC (&ldquo;Cova Capital Partners&rdquo;) as &ldquo;Agent&rdquo;)
to serve as exclusive placement agent for the Company on the terms and conditions set forth in this letter agreement (this &ldquo;Agreement&rdquo;)
for the purpose of raising up to $2.5 million, in the form of a registered direct public offering of the Company&rsquo;s common stock
(&ldquo;Common Stock&rdquo;), including, in the discretion of the Company, warrants to purchase Common Stock (&ldquo;Warrants&rdquo;
and together with Common Stock, the &ldquo;Securities&rdquo;), solely to accredited investors (as defined in Regulation D, promulgated
under the Securities Act of 1933, as amended) (the &ldquo;Financing&rdquo;). The parties acknowledge and agree that the exclusivity granted
hereby, and the term Financing, relates only to a registered direct public offering of the Securities undertaken by the Company through
a placement agent and does not include, without limitation, any private placement of the Company&rsquo;s securities, any other public
offering of the Company&rsquo;s securities, including any at-the-market offering, or any warrant exercises or exchanges.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">1. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
such capacity, the Agent shall be available for advice, and shall advise the Company with respect to such financial matters as the Company
shall from time to time request, including without limitation, matters relating to (a) the Company&rsquo;s business, operations, properties,
financial condition and prospects, and (b) the preparation of materials (collectively, the &ldquo;Documents&rdquo;) that include select
business and financial information about the Company and other relevant information for purposes of investor presentations and meetings
with current or potential investors and as investors or other interested parties may request. During the term of this Agreement, the
Agent shall serve as exclusive placement agent to the Company for a Financing, whether from institutional, retail or other investors.
The Agent is being retained to serve as Agent solely to the Company, and it is agreed that the engagement of the Agent is not, and shall
not be deemed to be, on behalf of, and is not intended to confer rights or benefits upon any shareholder or creditor of the Company or
upon any other person or entity. No one other than the Company is authorized to rely upon this engagement of the Agent or any statements,
conduct or advice of the Agent, and no one other than the Company is intended to be a beneficiary of this engagement. All opinions, advice
or other assistance (whether written or oral) given by the Agent in connection with this engagement are intended solely for the benefit
and use of the Company and will be treated by the Company as confidential, and no opinion, advice or other assistance of the Agent shall
be used for any other purpose or reproduced, disseminated, quoted or referred to at any time, in any manner or for any purpose, nor shall
any public or other references to the Agent (or to such opinions, advice or other assistance) be made without the express prior written
consent of the Agent, unless required by an applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><P STYLE="margin-top: 0; margin-bottom: 0">BioRestorative Therapies, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0">August 11, 2025</P><P STYLE="margin-top: 0; margin-bottom: 0">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">2. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will furnish the Agent with all information and material concerning the Company which the Agent reasonably requests in connection
with the performance of its obligations hereunder. The Company represents and warrants that all information made available to the Agent
by the Company will, at all times during the period of the engagement of the Agent hereunder, be complete and correct in all material
respects and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein not misleading in light of the circumstances under which such statements are made and it will continue to ensure that
all such information is current and accurate in all material respects. The Company further represents and warrants that any projections
provided to the Agent will have been prepared in good faith and will be based upon assumptions which, in light of the circumstances under
which they are made, are reasonable. The Company acknowledges and agrees that in rendering its services hereunder the Agent will be using
and relying upon, without any independent investigation or verification thereof, all information that is or will be furnished to the
Agent by or on behalf of the Company and on publicly available information, and the Agent will not in any respect be responsible for
the accuracy or completeness of any of the foregoing kinds of information. The Company understands that in rendering services hereunder
the Agent does not provide accounting, legal or tax advice and will rely upon the advice of counsel to the Company and other advisors
to the Company as to accounting, legal, tax and other matters relating to any services or transactions (including any potential Financing)
contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Agent&rsquo;s activities on behalf of the Company, the Company will furnish the Agent with all financial and other
information regarding the Company that the Agent reasonably believes appropriate to its assignment (all such information so furnished
by the Company, whether furnished before or after the date of this Agreement, being referred to herein as the &ldquo;Information&rdquo;).
The Company will provide the Agent with reasonable access to the officers, directors, employees, independent accountants, legal counsel
and other advisors and consultants for the Company. The Agent will maintain the confidentiality of the Information and, unless and until
such Information shall have been made publicly available by the Company or by others without breach of a confidentiality agreement or
obligation, shall disclose the Information only as authorized in writing by the Company or as required by law, rule or regulation, including
NASD Rule 2711, or by order of a governmental authority or court of competent jurisdiction. In the event that the Agent is legally required
to make disclosure of any of the Information, the Agent will give written notice to the Company prior to such disclosure, to the extent
that the Agent can practically do so. The provisions of this paragraph shall not be deemed to limit the provisions of Section 9 of the
letter agreement, dated December 17, 2024, between the Company and the Agent (the &ldquo;2024 Agreement&rdquo;), which shall continue
in full force and effect in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><P STYLE="margin-top: 0; margin-bottom: 0">BioRestorative Therapies, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0">August 11, 2025</P><P STYLE="margin-top: 0; margin-bottom: 0">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">3. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company agrees as compensation for its services under this Agreement to pay the Agent as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) (i)&nbsp;If
a Financing is consummated during the term of this Agreement with or without the Agent, or (ii)&nbsp;the Company enters into a definitive
agreement with respect to a Financing during the term of this Agreement or during the Residual Period (as defined in Section 5 below)
and the Financing is thereafter consummated, then the Company shall pay to the Agent, upon each closing or consummation of the Financing
(&ldquo;Closing&rdquo;), a cash placement fee (the &ldquo;Financing Fee&rdquo;) equal to six percent&nbsp;(6.0%) of any gross proceeds
received by the Company at such Closing, but only with respect to Securities that are sold in the Financing to an investor who was introduced
to the Company by the Agent during the term of this Agreement as evidenced by a list of persons and entities prepared by the Agent and
approved in writing by the Company (the &ldquo;Agent Investors&rdquo;). Any Financing Fee shall be due and payable immediately upon Closing
of a Financing. The Financing Fee shall be deemed earned when paid and shall be non-refundable. The Financing Fee is not negotiable or
subject to any reduction, set-off, counterclaim or refund for any reason or matter whatsoever. In addition, in the event Warrants are
issued by the Company pursuant to the Financing, the Company shall issue to the Agent or its designees, at the Closing, warrants (the
&ldquo;Placement Agent Warrants&rdquo;) to purchase that number of shares of Common Stock (the &ldquo;Placement Agent Warrant Shares&rdquo;)
equal to six percent (6%) of the number of shares of Common Stock issued to the Agent Investors in the Financing, excluding any shares
of Common Stock issuable upon exercise or conversion of securities, including Warrants, issued in the Financing. The Placement Agent
Warrants (i) shall have a 5-year term, and (ii) shall have a per share exercise price equal to the exercise price per share of the Warrants
issued in the Financing. For the avoidance of doubt, no fee, cash or other amount shall be due from the Company to the Agent as the result
of the exercise of any Warrants or similar rights or the conversion or exchange of any convertible or exchangeable securities issued
in connection with the Financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) In
addition to the fees described in this Section 3 and the obligation of the Company to pay certain expenses set forth in Section 7 and
whether or not any Financing is consummated, the Company will pay all of the Agent&rsquo;s reasonable out-of-pocket expenses directly
to the Agent (including, without limitation, the reasonable expenses relating to document and presentation materials, travel, external
database and communications services, courier and delivery services, and the reasonable fees and expenses of outside legal counsel),
incurred by the Agent in connection with this engagement provided that the Company shall have given its express written permission to
the incurrence thereof and to the expressed maximum amount that can be incurred pursuant to such permission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) The
Company shall have the absolute right, in its sole discretion, to reject the terms and conditions of any Financing proposed by the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">4. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with engagements of the nature covered by this Agreement, it is the Agent&rsquo;s practice to provide for indemnification,
contribution, and limitation of liability. By signing this Agreement, the Company agrees to the provisions attached to this Agreement
(Attachment A), which provisions are expressly incorporated by reference herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><P STYLE="margin-top: 0; margin-bottom: 0">BioRestorative Therapies, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0">August 11, 2025</P><P STYLE="margin-top: 0; margin-bottom: 0">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">5. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&ldquo;Residual Period&rdquo; shall extend for twelve (12) months from the earlier of (a) the date of termination of this Agreement (subject
to Section 8) or (b) the date of automatic expiration of this Agreement, in each case solely with respect to the Agent Investors who
were participants in any Financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">6. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Party represents and warrants to the other party that this Agreement has been duly authorized by such party and represents the legal,
valid, binding and enforceable obligation of such party and that neither this Agreement nor the consummation of any Financing contemplated
hereby requires the approval or consent by such party of any governmental or regulatory agency or violates any law, regulation, contract
or order binding on such party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">7. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a Financing, the Company shall make or cause to be made state &ldquo;blue sky&rdquo; applications in such states and jurisdictions
as shall be required by law in connection with a Financing. It shall be the Company&rsquo;s obligation to bear all blue sky counsel fees
and expenses; provided, however, that no such fees and expenses shall be payable unless the Company has given its prior written approval
to the incurrence thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">8. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
party agrees to comply with all applicable federal and state securities laws in connection with any Financing contemplated by this Agreement.
The Agent&rsquo;s engagement and the term of this Agreement shall automatically expire upon the earlier of (a) ninety (90) days from
the date of this Agreement or (b) the Closing of the Financing, unless extended in writing by the Agent and the Company. Either Cova
Capital Partners (on behalf of the Agent) or the Company may terminate this Agreement at any time, with or without cause, upon fourteen
(14) days&rsquo; written notice to the other party. The provisions of Sections 2, 3, 4, 5 (including, without limitation, Attachment
A), 6, 7, 9, 10, 11, 12 and 13 hereof shall survive any termination of this Agreement. Notwithstanding the foregoing, Cova Capital Partners
(on behalf of the Agent) may immediately terminate this Agreement at any time if (each a &ldquo;Cova Capital Partners Unilateral Termination&rdquo;)
(i) it reasonably determines that the results from its due diligence review of the Company&rsquo;s business, management and future prospects
are unsatisfactory or (ii) its internal approval committee does not approve proceeding with the Financing. In the event of a Cova Capital
Partners Unilateral Termination or a termination of this Agreement by Cova Capital Partners (on behalf of the Agent) without cause, there
shall be no Residual Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">9. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company agrees that, following any future closing or consummation of any Financing, the Agent shall have the right to place advertisements
in financial and other newspapers and journals at its own expense, describing its services to the Company and a general description of
the Financing provided that the Agent will submit a copy of any such advertisements to the Company for its prior written approval, which
approval shall not be unreasonably withheld or delayed. In addition, the Company agrees to include in any press release or public announcement
announcing a Financing, if any, a reference to the Agent&rsquo;s role as financial advisor and placement agent to the Company with respect
to such Financing, provided that the Company will submit a copy of any such press release or public announcement to the Agent for its
prior approval, which approval shall not be unreasonably withheld or delayed. The Company agrees that, for a period of forty-five (45)
days following the closing of the Financing in the amount of at least $2.5 million, it will suspend its at-the-market offering of Common
Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><P STYLE="margin-top: 0; margin-bottom: 0">BioRestorative Therapies, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0">August 11, 2025</P><P STYLE="margin-top: 0; margin-bottom: 0">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">10. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
 In the event that at least $2.5 million in Securities are sold by the Company during the term of this Agreement to Agent Investors
pursuant to the Financing, then the Agent shall have the rights set forth in this Section 10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) In
the event, during the Applicable Period (as hereinafter defined), the Company seeks to raise up to $2.5 million in Securities (the &ldquo;Initial
Additional Financing&rdquo;), it shall notify the Agent of such desire (the &ldquo;Initial Additional Financing Notice&rdquo;). Thereupon,
the Company and the Agent shall negotiate in good faith the terms of an engagement agreement pursuant to which the Agent shall serve
as placement agent or underwriter for the Initial Additional Financing (the &ldquo;Initial Additional Financing Engagement Agreement&rdquo;).
In the event, within fifteen (15) days following the date of the Initial Additional Financing Notice, the Company and the Agent do not
enter into the Initial Additional Financing Engagement Agreement, for any reason, then the Company shall be free to seek to raise funds
pursuant to the Initial Additional Financing in such manner as it determines, in its sole discretion, including pursuant to another placement
agent or underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) In
the event that the Company and the Agent enter into the Initial Additional Financing Engagement Agreement and at least $2.5 million in
Securities are sold by the Company to Agent Investors pursuant to the Initial Additional Financing, then the provisions of paragraph
(b) above shall apply in like manner with respect to an additional financing by the Company of up to $2.5 million in Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) For
purposes hereof, the term &ldquo;Applicable Period&rdquo; shall mean the twelve (12) month period following the date of this Agreement;
provided, however, that the Applicable Period shall terminate earlier in the event (i) the Initial Additional Financing Notice is sent
by the Company and the Initial Additional Financing Engagement Agreement is not entered into between the Company and the Agent for any
reason or (ii) the Company has raised at least $7.5 million in gross proceeds from the sale of Securities following the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) For
the avoidance of doubt, the provisions of this Section 10 shall apply only with respect to a financing of up to $2.5 million in Securities.
Accordingly, in the event the Company seeks to raise more than $2.5 million in Securities pursuant to a financing, the Agent shall not
have the rights set forth in this Section 10; however, in such event, the Company shall use reasonable commercial efforts to allow the
Agent to participate in such financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><P STYLE="margin-top: 0; margin-bottom: 0">BioRestorative Therapies, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0">August 11, 2025</P><P STYLE="margin-top: 0; margin-bottom: 0">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">11. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company represents and warrants that there are no brokers, representatives or other persons which have an interest in any compensation
due to the Agent from any advice or proposed Financing contemplated herein. The Company acknowledges and agrees that the Agent is a full-service
securities firm and as such from time-to-time may effect transactions for its own account or the accounts of its customers and hold long
or short positions in debt or equity securities of the companies which may be the subject of a potential Financing. It is understood
that the Agent&rsquo;s obligation under any definitive agreement as placement agent is to use its commercially reasonable efforts throughout
the period for which it acts as the Company&rsquo;s exclusive agent as described herein, including to use its best efforts to complete
any proposed Financing contemplated by this Agreement. The Agent&rsquo;s engagement is not intended to provide the Company or any other
person or entity with any assurances that any Financing or other transaction will be consummated, and in no event will the Agent or any
of its affiliates be obligated to purchase securities of the Company for its own account or the accounts of its customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">12. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms and provisions of this Agreement are solely for the benefit of the Company and the Agent and the other Indemnified Persons and
their respective successors, assigns, heirs and personal representatives, and no other person or entity shall acquire or have any right
by virtue of this Agreement. The Company and the Agent acknowledge and agree that the Agent is acting as an independent contractor, and
is not a fiduciary of, nor will its engagement hereunder give rise to fiduciary duties to, the Company or its board of directors. The
Agent shall not have the power or authority to enter into any agreement on behalf of the Company or otherwise bind the Company to any
obligation. This Agreement represents the entire understanding between the Company and the Agent with respect to the Agent&rsquo;s engagement
hereunder, and all prior discussions are merged herein (except with respect to the Agent&rsquo;s confidentiality obligations as provided
for hereunder). The parties acknowledge and agree that the engagement provided for in the 2024 Agreement terminated effective as of June
17, 2025, and, except as provided for in Section 11 of the 2024 Agreement, is no longer in effect. This Agreement may be executed in
two or more counterparts (including fax or electronic counterparts), all of which together will be considered a single instrument. THIS
AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO SUCH STATE&rsquo;S
PRINCIPLES OF CONFLICTS OF LAWS, AND MAY BE AMENDED, MODIFIED OR SUPPLEMENTED ONLY BY A WRITTEN INSTRUMENT EXECUTED BY EACH OF THE PARTIES
HERETO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">13. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Dispute
Resolution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) All
disputes, claims, or controversies arising out of or relating to this Agreement or the transactions contemplated hereby that are not
resolved by mutual agreement shall be resolved solely and exclusively by binding arbitration to be conducted before JAMS, The Resolution
Experts, or its successor (&ldquo;JAMS&rdquo;). The arbitration shall be held in New York City, New York before three arbitrators, one
chosen by the Company, one chosen by Cova Capital Partners, LLC (on behalf of the Agent) and one reasonably agreed upon between the Company
and Cova Capital Partners (on behalf of the Agent) (or, if not agreed upon within fifteen (15) days of submission of a proposed third
arbitrator by one party to the other party, then by JAMS). The arbitration shall be conducted in accordance with the rules and regulations
promulgated by JAMS unless specifically modified herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><P STYLE="margin-top: 0; margin-bottom: 0">BioRestorative Therapies, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0">August 11, 2025</P><P STYLE="margin-top: 0; margin-bottom: 0">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties covenant and agree that they will participate in the arbitration in good faith and that they will share equally its costs, except
as otherwise provided herein. The arbitrators may in their discretion assess costs and expenses (including the reasonable legal fees
and expenses of the prevailing party) against any party to a proceeding. Any party refusing to comply with an order of the arbitrators
shall be liable for reasonable costs and expenses, including reasonable attorneys&rsquo; fees, incurred by the other party in enforcing
the award. This Section 13 applies equally to requests for temporary, preliminary or permanent injunctive relief, except that, in the
case of temporary or preliminary injunctive relief, any party may proceed in court without prior arbitration for the limited purpose
of avoiding immediate and irreparable harm. The provisions of this Section 13 shall be enforceable in any court of competent jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties shall bear their own attorneys&rsquo; fees, costs and expenses in connection with the arbitration; provided, however, the parties
agree that the prevailing party shall be entitled to, and the arbitrators shall award to the prevailing party, its reasonable attorneys
fees, costs and expenses in the event such party completely prevails or prevails in all material respects in the arbitration decision
as determined by the arbitrators. The parties will share equally in the fees and expenses charged by JAMS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Each
of the parties hereto irrevocably and unconditionally consents to the exclusive jurisdiction of JAMS to resolve all disputes, claims
or controversies arising out of or relating to this Agreement or the transactions contemplated hereby and further consents to the jurisdiction
of the courts of New York for the purposes of enforcing the arbitration provisions of Section 13(a) of this Agreement. Each party further
irrevocably waives any objection to proceeding before JAMS based upon lack of personal jurisdiction or to the laying of venue and further
irrevocably and unconditionally waives and agrees not to make a claim in any court that arbitration before JAMS has been brought in an
inconvenient forum. Each of the parties hereto hereby consents to service of process by registered mail to the respective address of
each party (attention to the Chief Executive Officer). Each of the parties hereto agrees that its submission to jurisdiction and its
consent to service of process by mail is made for the express benefit of the other parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">14. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Agent may assign, with the prior written consent of the Company, all or a portion of its duties hereunder to one or more investment banks.
Notwithstanding any other entity&rsquo;s participation in any Financing hereunder as a result of such assignment, compensation detailed
in Section 3 of this Agreement will be solely due and payable by the Company to the Agent on the proportional basis detailed in Section
3 of this Agreement, unless otherwise agreed in writing. The Agent will compensate any such investment bank or financial advisor directly
pursuant to arrangements between the Agent and such investment bank or financial advisor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Remainder
of page intentionally left blank. Signature page follows.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><P STYLE="margin-top: 0; margin-bottom: 0">BioRestorative Therapies, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0">August 11, 2025</P><P STYLE="margin-top: 0; margin-bottom: 0">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing correctly sets forth the entire understanding and agreement between the Agent and the Company, please so indicate in the
space provided for that purpose below and return an executed copy to us, whereupon this letter shall constitute a binding agreement as
of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alere Financial Partners,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
division of Cova Capital Partners LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    Odenthal</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    of Investment Banking, Alere Financial Partners</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ed
    Gibstein</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO,
    Cova Capital Partners, LLC</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
    Therapies, Inc.</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><P STYLE="margin-top: 0; margin-bottom: 0">BioRestorative Therapies, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0">August 11, 2025</P><P STYLE="margin-top: 0; margin-bottom: 0">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATTACHMENT A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDEMNIFICATION, CONTRIBUTION AND<BR>
LIMITATION OF LIABILITY PROVISIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company agrees to indemnify and hold harmless the Agent and its affiliates and their respective
                                            officers, directors, employees and agent, and any persons controlling the Agent or any of
                                            its affiliates within the meaning of Section 15 of the Securities Act of 1933 or Section
                                            20 of the Securities Exchange Act of 1934 (the Agent and each such other person or entity
                                            being referred to herein as an &ldquo;Indemnified Person&rdquo;), from and against all claims,
                                            liabilities, losses or damages (or actions in respect thereof) or other expenses which are
                                            related to or arise out of (i) actions taken or omitted to be taken (including any untrue
                                            statements made or any statements omitted to be made) by the Company or its affiliates, (ii)
                                            actions taken or omitted to be taken by an Indemnified Person with the written consent or
                                            in conformity with the actions or omissions of the Company or its affiliates, or (iii) the
                                            Agent&rsquo;s activities on behalf of the Company as contemplated by this Agreement. The
                                            Company will not be responsible, however, for any losses, claims, damages, liabilities or
                                            expenses to the extent they are finally determined by a court or arbitral tribunal of competent
                                            jurisdiction to have resulted from such Indemnified Person&rsquo;s bad faith, gross negligence
                                            or willful misconduct. In addition, the Company agrees to reimburse each Indemnified Person
                                            for all reasonable out-of-pocket expenses (including reasonable fees and expenses of counsel)
                                            as they are incurred by such Indemnified Person in the third party claim and which are necessary
                                            for the defense of any such action or claim.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            for any reason the foregoing indemnity is unavailable to an Indemnified Person or insufficient
                                            to hold an Indemnified Person harmless, then the Company shall contribute to the amount paid
                                            or payable by such Indemnified Person as a result of such claim, liability, loss, damage
                                            or expense in such proportion as is appropriate to reflect not only the relative benefits
                                            received by the Company on the one hand and the Agent on the other, but also the relative
                                            fault of the Company and the Agent, as well as any relevant equitable considerations, subject
                                            to the limitation that in any event the aggregate contribution of all Indemnified Persons
                                            to all losses, claims, liabilities, damages and expenses shall not exceed the amount of fees
                                            actually received by or payable to the Agent pursuant to this Agreement. It is hereby further
                                            agreed that the relative benefits to the Company on the one hand and the Agent on the other
                                            with respect to any Financing or proposed Financing contemplated by this Agreement shall
                                            be deemed to be in the same proportion as (i) the total value the Financing bears to (ii)
                                            the fees paid or payable to the Agent with respect to such Financing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; width: 0; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            Indemnified Person shall have any liability to the Company or any other person in connection
                                            with the services rendered pursuant to this Agreement, except to the extent any liability
                                            for losses, claims, damages or liabilities has been finally determined by a court or arbitral
                                            tribunal of competent jurisdiction to have resulted from such Indemnified Person&rsquo;s
                                            bad faith, gross negligence or willful misconduct.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><P STYLE="margin-top: 0; margin-bottom: 0">BioRestorative Therapies, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0">August 11, 2025</P><P STYLE="margin-top: 0; margin-bottom: 0">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; width: 0; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            indemnification is to be sought hereunder by any Indemnified Person, then such Indemnified
                                            Person shall notify the Company promptly of the commencement of any action or proceeding
                                            in respect thereof; provided, however, that the failure so to notify the Company promptly
                                            shall not relieve the Company from any liability that it may otherwise have to such Indemnified
                                            Person except and only to the extent that the Company is materially adversely affected by
                                            such Indemnified Person&rsquo;s failure to provide prompt notice. Following such notification,
                                            the Company may elect in writing to assume the defense of such action or proceeding, and,
                                            upon such election, it shall not be liable for any legal costs incurred by such Indemnified
                                            Person (other than reasonable costs of investigation) in connection therewith, unless (i)
                                            the Company has failed to provide counsel reasonably satisfactory to such Indemnified Person
                                            in a timely manner or (ii) representation of such Indemnified Person by counsel provided
                                            by the Company would present such counsel with a conflict of interest.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; width: 0; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company agrees that it will not settle or compromise or consent to the entry of any judgment
                                            in any pending or threatened claim, action, suit or proceeding in respect of which indemnification
                                            may be sought from the Company by any Indemnified Person (whether any Indemnified Person
                                            is an actual or potential party to such claim, action, suit or proceeding) unless such settlement,
                                            compromise or consent includes an unconditional release of Indemnified Persons hereunder
                                            from all liability arising out of such claim, action, suit or proceeding.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; width: 0; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            the extent officers or employees of the Agent appear as witnesses, are deposed, or otherwise
                                            are involved in or assist with any action, hearing or proceeding related to or arising from
                                            any Financing or proposed Financing contemplated by this Agreement or the Agent&rsquo;s engagement
                                            hereunder, or in a situation where such appearance, involvement or assistance results from
                                            the Agent&rsquo;s engagement hereunder, the Company will pay the Agent, in addition to the
                                            fees set forth above, the Agent&rsquo;s reasonable and customary per diem charges. In addition,
                                            if any Indemnified Person appears as a witness, is deposed or otherwise is required to be
                                            involved in any action relating to or arising from any Financing or proposed Financing contemplated
                                            by this Agreement or the Agent&rsquo;s engagement hereunder, or in a situation where such
                                            appearance, involvement or assistance results from the Agent&rsquo;s engagement hereunder,
                                            the Company will reimburse such Indemnified Person for all reasonable expenses (including
                                            reasonable fees and expenses of counsel) incurred by it by reason of it or any of its personnel
                                            being involved in any such action.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; width: 0; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
                                            parties waive any right to a trial by jury with respect to any claim or action arising out
                                            of this Agreement or the actions of the Agent, and consents to personal jurisdiction, service
                                            of process and venue as provided for in this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; width: 0; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            provisions of this Attachment A shall be in addition to any liability the Company may have
                                            to any Indemnified Person at common law or otherwise, and shall survive the termination of
                                            this Agreement and the closing or consummation of any Financing or proposed Financing contemplated
                                            by this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex99-1_001.jpg" ALT="" style="width:200px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioRestorative
Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MELVILLE,
N.Y., October 6, 2025 &mdash; BioRestorative Therapies, Inc. (&ldquo;BioRestorative&rdquo;, &ldquo;BRTX&rdquo; or the &ldquo;Company&rdquo;)
(NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has entered into definitive agreements
with several accredited and/or institutional investors for the sale of 678,125 shares of the Company&rsquo;s common stock at an offering
price of $1.60 per share in a registered direct offering. The Company&rsquo;s stock closed at $1.50 per share on October 3, 2025. In
a concurrent private placement offering, the Company also agreed to issue to the investors in the registered direct offering unregistered
warrants to purchase up to an aggregate of 508,594 shares of the Company&rsquo;s common stock (the &ldquo;Unregistered Warrants&rdquo;),
representing 75% warrant coverage. The Unregistered Warrants will have an exercise price of $2.75 per share and will be exercisable commencing
six months from the date of issuance until the five year anniversary of the date of issuance. The gross proceeds of the offering will
be $1.085 million, before deducting placement agent fees and other estimated offering expenses. The closing of the offering is expected
to take place on or about October 8, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds of the offering in connection with its clinical trials with respect to its lead cell therapy
candidate, BRTX-100, pre-clinical research and development with respect to its metabolic ThermoStem<SUP>&reg;</SUP> Program, the development
of its commercial biocosmeceuticals platform and for general corporate purposes and working capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We
appreciate the support of this high-conviction group of existing and new healthcare specialist investors, anchored by our largest institutional
shareholder,&rdquo; said Lance Alstodt, Chief Executive Officer of BioRestorative. &ldquo;Members of our executive team also participated.
With this investment, together with our existing cash, we believe that we are well-positioned to continue executing on our strategic
goals.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alere
Financial Partners (a division of Cova Capital Partners, LLC) acted as the exclusive placement agent for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares in the offering are being offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-269631)
previously filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) and declared effective by the SEC on February
14, 2023. The offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective
registration statement, relating to the offering, which will be filed with the SEC and will be available on the SEC&rsquo;s website located
at http://www.sec.gov. Electronic copies of the final prospectus supplement and accompanying prospectus may also be obtained, when available,
from Cova Capital Partners, LLC, 6851 Jericho Turnpike, Suite 205, Syosset, New York 11791, or by telephone at (866) 772-8081.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Unregistered Warrants are being offered in the concurrent private placement offering pursuant to an exemption from the registration requirements
of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), provided for in Section 4(a)(2) of the Securities Act and/or
Regulation D promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
BioRestorative Therapies, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
(www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described
below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also
operate a commercial BioCosmeceutical platform:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Disc/Spine Program (brtxDISC&trade;): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person&rsquo;s
own) cultured mesenchymal stem cells collected from the patient&rsquo;s bone marrow. We intend that the product will be used for the
non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100
production process utilizes proprietary technology and involves collecting a patient&rsquo;s bone marrow, isolating and culturing stem
cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the
patient&rsquo;s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and
who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain
arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) Investigational New
Drug (&ldquo;IND&rdquo;) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Metabolic Program (ThermoStem<SUP>&reg;</SUP>): We are developing cell-based therapy candidates to target obesity and metabolic disorders
using brown adipose (fat) derived stem cells (&ldquo;BADSC&rdquo;) to generate brown adipose tissue (&ldquo;BAT&rdquo;), as well as exosomes
secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial
preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well
as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity
and diabetes. BADSC secreted exosomes may also impact weight loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using
our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic
serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic
effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family
of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the
emerging BioCosmeceuticals space.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
press release contains &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the
forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company&rsquo;s
latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking
statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made
as of the date hereof and the Company undertakes no obligation to update such statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTACT:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
Kilmer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Direct:
(646) 274-3580</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
<U>skilmer@biorestorative.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "L!BL# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK-O-9@MB43][(
M.P/ _&L:XU6[N"1YFQ?[J<4KC29T\D\40_>2(OU.*K/JUBG_ "W!_P!T$USL
M6GW=P=RPN<_Q-Q_.K::#='[SQK^.:5V.R-,ZW9 _><_\!I/[<LL_>?\ [YJC
M_P (]+_S\)_WR:1O#\X'$T9^H(HU"R-)=8L6_P"6V/JIJ=+ZUD^[<1G_ (%B
MN>DT:]CY"*X_V6JE)%)$VV1&0^C#%%V.R.U!!&0<BEKBDEDC.8Y'7_=.*LIJ
MEZG2X8_[P!HYA<IUE(&!Z$50T^1]0TYOM/.XE21QD5%)H-LP^221#]<BF*QJ
MT5Q]W;2V4YB=O<$'@BHO-D_YZ/\ ]]&E<?*=K2;E]1^=<I;Z=>7:"1%^0]&9
MJL'0KS&=T7TW'_"G<+(Z2BN1FMKRR.7$B#^\K<?F*E@UB[A/+^8OH_\ C1<.
M4ZFBJ5CJ4-Z-H^20=4/]*NTR0HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH 1F"*68@*!DD]JYS4=7>X)B@)6+H3W;_P"M2ZOJ)GD-O$W[
MI3\Q'\1_PJG8637MP(QPHY9O05+9:75BV5A->OA!M0?><]!716NFVUH 53<_
M]]N3_P#6JS%$D$2QQJ%5>@%/II$MW"BBBF(**** "F211RJ5D164]B,T^B@#
M$OM#&TR6N<]?+/\ 2L(@J2",$<$&NXKG]>M!'(MR@P'X;Z^M2T6F:.C+C2XO
M<D_K5^J6DC&F0?0_S-7:I$O<P_$*C$#XYR16'6_XA'[B$_[1_E6!4/<M;'5:
M/_R"X?Q_F:O51T?_ )!</X_S-7JI$/<1E5U*L 5/4&N9U73OL<@DC'[ESP/[
MI]*Z>H+VW%S:21'J1Q]>U#0)V./5F1PZ$JP.01VKJ]-O?MMJ'/$B\./?UKD^
MG6M/0YC'?^7GY9%(_$<U*+:.EHHHJS,**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA^T6TD.<;UQGTH!$&EC&F0?[O]:N5%;0_9[:.$'.Q<9]:EH Q_$'_'M#_O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M34V*Q(TJ J0I;#<\<#^E,U#Q>VDZ9+J%_I%W%!!<>1<$,K&/.W#\'YE.X=*
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M3_"8U^;3)_+V+(T D0NJ-T.<X/4<9[UI.B:IHQ6]M JS19>"0AL<="1QGZ4
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MKMQ.&=&6FS.'#8E5EYHL5EZIXCTK1FVZA=>1QG+1N1^8&*U*YSQ;=1RZ->6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W=I;WUI+:W4
M*302J4DC<9# ]JFJ*XMXKJW>"9=T3C:RY(R/3B@#AM-\/Z9>Z_'%I-L(=&TL
M2 R*2PFN7780"2<A%)]LG':JEK,UO\+KSPXX U:%)-.%L?ONS$JA [@JP.?3
M/I7HL$$-M D$$211(,*B* %'H *4PQ&42F-/, P'VC('UH P-;GM_#W@2=9Y
MTC$%B84+,!N8)M 'OFL#7([JW\0Z)K6A,DHU2'^SIW0Y7!&Y),CKMPQ_#%=[
M+!%.H6:))%!R Z@\_C2I%'&BI'&BJO154 "@#A;F\L--^*6AZ>MQ%&(]+EAP
MSC.2RE0?<[<^]0V5Q'+XN\4RQ:Y#9PI=6K/EDVR*L:[AN/(Z$<5WKV=K)(9'
MMH6<G.YD!/YTTV%FPP;2 @<X,8_PH XO7]1AO_%_A3[!J$4$TL-T\3NH. R+
ML)4^N*R8]0M['P+XKT[576WU[R[AKP2-@W#,I"R)GJI&  .E>F&TMFD$C6\1
M<8PQ09&.G-++:V\[!IH(I".A= <?G0!YU:7)L-<\/:AK5TESI#62QV%TH"QV
MTQ4!@^..1P&/3I5VWF@U+QKXNLK2]A^T7%A#'$4D!(;8PR/ID5W/V>#R?)\F
M/RO[FT;?RID=G:PN'BMH4<=&5 "* .2\"ZQ967A*VTV^ECL;W38S#<P3D(RE
M2?FP>H(YR*I^+[Z+4I_"Z66H+87%S/(\$CX#1@PN%8J?<C\_6N[DMH)G#RP1
MNR]"R D4DEI;2N'DMXG<=&9 30!SGA+Q';7<;Z+=K!9:Q8'R9[17&"1_$GJ#
MU]>>:77KRQU+7=.\.->JDCL;F9(I]D@"?= (.02Q!]?E-=%]DMO.\[[/%YN<
M[]@W9^M'V2V,WG?9XO-SG?L&<_6@#@KAK'P;\1K"1KUA;:O;-;SFZN2["1#E
M&)8DXP=OI5A[&>V\=7>EPQEM-UE4OY&'W4:,@2#_ ('\GYUVLMI;3MNEMXI&
MQC+H"<5*%48PH&!@<=!0!Q?C2>,>(_"T(O4MI1=R-O)4E!Y3#.#QC/'/K2ZC
MJVGP:%'8W>K6]Y+%>VZ33,PVL6F#8/;[O4=JZ^2UMY6+201.Q&"60$X]*9]@
ML]@3[)!M!R!Y8Q_*@#@5T^]\->)--TB)#/H%W?">S?.?LKA6+1_[IZBM#[;;
M:#\2=3GU.9+6WU&S@\B>4[8V:,L&7<>,\@XKM=BX VC Z<=*;+#%,NV6-)%Z
MX=010!@6US;M9ZYJIE5;2=R8Y6.%95B5=P/H2#BL'P+=QV7AW09+C6D=)+5;
M>.R^7<)&88P!R<8/7I7>O%')'Y;QHR?W6&1^51K9VJ2"1;:%9!T8( 1^- %;
M2=9L]:@GEM#)^XF:"19$*,KKU!!_ _C7'Z[X;T>;47T71[&..]U%@^H2QDX@
M@W L<9PI?& !C.3Z5VUE80V"2B+<SS2&661SEG8]R?H /H!3K2PM;%9!;0)'
MYC%Y".KMZD]2?K0!RWCV\L["QT6*:>*$?VI;$!G PJMR?H*T?&MS!'X%UJ1Y
MHU22QE5&+ !B4. /7-;<MK;SD&:"*0@8!= <?G2O;PR1B-X8VC7HK*"!^% '
MFGB*"6/X7&Z?Q')+;O:Q;8F6((_W?E!"Y/YYXKT(7ELNC"[-Q%]G\G=YN\;<
M8ZYZ5.;2V:)8C;Q&-3E5*# _"G?9X?)\GR8_*_N;1M_*@#SKX>Z#H.L>"M-N
MC%$]Y'(9'D1_G1EE++D9XX K3T77-*MO$WBZ>;4K5(Q<0G<TJC(6!0<<\X((
M_"NQBMX(-WDPQQ[NNQ0,_E4?]G6/_/G;_P#?I?\ "@#D;FX_L[Q_9Z]=J\>F
M7^G"U6:08$$F[> _]W</7O3M9B_M[QOHG]G2!Q817#W-Q&<J@=-JJ2.Y/./:
MNT9%="CJ&4\$$9!IL44<*;(HTC0?PJH H XWP-J%MI'AB/1]3E2SOM-WQSQS
M,%+#<2'&>JD'.17,7J?8/ 6H3W+"T74]=6ZM8I<*5C,R$'!]E+5ZQ);PRNKR
M0QNR_=+*"1]*26W@GQYT,<F.F]0<?G0!Q6F7!TWQ[=C7YTDN+N%5TR]P%C>'
M.3$.P?//O7=5&T$+HJ-$C*N-H*@@8Z8J2@#P7XP,3XV4$\"TCQ^;5[!X0(;P
M=HY!R/LD?\J\O^--BT>N:?? '9- 8\^ZG/\ )A7:_"S5%U#P3;P[@9;-F@<>
M@SE?T(_*O4KKFPD)+H>50?+BYQ?4[6BBBO+/5"BBB@ KQ7X;?\E.U7Z3_P#H
MP5[57@?A+3KS4_B#J<-EJ<NG2AIV,T2AB1OZ8-=^%2=.HF^AP8MM5*;2OJ>^
M4 @]#7GFJ^#_ !8ME/+;>-;N1T0E8V38&P.F5/'UQ76>%HC#X4TE&R7^R1EB
M3DEBH)_4US3IQC'F4KG3"I*4N5QL>8?&7_D8='_ZXG_T.O9J\8^-#;=>TEL9
MQ QQ_P "KLXOB7I9MO.N-.U>W(7<RM9L0/Q'%==6G*="GRJ^YR4JD85ZG,[;
M&1\:"G_".:>IY<W?RCO]PYKL_"MA)IGA32[.48DBMU#CT.,D?K7%:1=P?$KQ
M8NHRXCTS2,&"T<@O([?QL.PX'Y5Z;6-9N%.-%[K5_,UHI3J2K+9Z+Y!7BOBG
M_DM]A_UWM?Z5[57BOBG_ )+?8?\ 7>U_I5X+XY>C)QOP1]4>F^(6^:W7V8_R
MK$K:\0C][ ?]EOZ5BUYSW/26QYWXN&/'ND^YA_\ 1E>^5X%XM.?'VE#T,'_H
MRO?:]#$?PJ7H>=A_XU7U/-/C3_R+>G_]?G_LC5U'@'_D1-'_ .O<?S-<O\:?
M^1;T_P#Z_/\ V1JZCP#_ ,B)H_\ U[C^9IS_ -TCZLF'^]R]$='7.^/)_L_@
M;6'S@FW*C\>/ZUT5<5\5KCR? -XN>99(T_\ '@?Z5ST%>K%>:.FN[4I/R9Y5
M/:3^#;KPUX@M0VRXMTF(]6'#K^((_.OH2SNH;ZSAN[=P\,R"1&'<$9%<1XC\
M-_VO\+;6WC3-S:6D<\/'.509'XC(_*J7P?U_[;HLVC3/F:S.^,$\F-C_ $.?
MS%=E=^VI>TZQ=GZ=#BPZ]C5]GTDKKUMJ>E5YMXGC_P"$P\<Q:$,M8:5 UQ=8
MZ&0CY5_E^M=WK&IPZ-H]WJ,Y_=V\9<CU/8?B<"N8^'&ERQ:%/J]Z,WVKRFYD
M8]=I^Z/U)_&N:C[D75^2]7_DCJK>_)4OF_1?YLYCX)38&LVQZYB?'_?0->N5
MXQ\)G^S>-M9LSQF)^/\ =DQ_6O9ZTQR_?-][?D9X%_N$NU_S.*^)VH20>&4T
MRW/^E:I,ML@'7!/S?T'XUR/Q2T'^QK70=1LAM^R(MJ64="OS(?T:M'7M9T^Y
M^+=C'J%Y#!8Z1$7+2-A3*1G'UY7\JTO&VO>&=>\(W]E'K5D\^SS(0)!DNO(
M^O3\:VH\U)TTEIN_GI^1A6Y:JJ-O79?+7\S8DU./6?#6F:C'TN$#D>AQR/P.
M:S7^XWT-<G\.M8^T>'IM(D;Y[6;S8P?[C#G\C_.NL?[C?0UP8BG[.JXGHX:I
M[2DIG#>'?#Q\2^#+FU$;EXKN1H9%0G8^!^A[U3\+^*-5\%:G+HNH-+!;>9AX
MW7_5,?XAGL?_ *]=W\'F!\,WZ_W;]_\ T%:O?$+P0GB?3_M=HJKJENOR'IYJ
M_P!P_P!#7HNK%59TJOPM_<>:J4G2A6I?$E]Y8;5+R5 3<L589!7 R/J*S[OY
MK.XSSF-LY^AKE_ASXS^QSCPUKW$6[R[=YA_JF_YYMGH,]/0\5Z-J^AJ;2=[7
M@^6V4/T[5Y]:A*C/E9Z%#$1K0NCD_A+J4-MX4:WERN;IR'[=%KTM6#*&4@@]
M"*\<^'HQX;<?]/+_ ,A7<V&I2V3@9+0GJGI]*K%/]_+U%A8_N(>AY%XL@:Z^
M*EU;I*T3RWT2+(O5"=HR/IUKT^;P7XD\@I!XXOPV./,B!_4'->::W(DWQ>\Q
M#E6U* @_BE?0E=V*JRA&G;MV7D<&%I1G*I?OW9X(TOB?X9:_)=7445T+L_/.
MX+B<#DX?J#[5Z_X7\56'BK3?M5F2DB<30,?FC/\ 4>AJ?Q%H=OXAT.YTZX4?
MO%_=L1]QQ]UA]#7@W@C5;CPUXWMD<E%>;[+<IGC!.W]#S^%*T<53<K6FOQ!N
M6$J*-[P?X'T=7 3O_;_Q=@@'S6VB6QD;T\UO_P!8_(UW%Y=1V-E/=S'$4,;2
M.?8#)KS#X=>(M&MH=6U75M4M8+_4;MG9)' 8(.1^I/Y"N6A%\LII>7W_ / .
MNO)<T8-^?W?\$R]&;_A#?C%<6+?):7<AC [;9/F3\C@?G7M5>'_%34-(U'4-
M-U32-2MY[A 8Y!"^2,'<K?J?TKUWP[JJ:YX?L=24C]_$&;V;HP_,&M<5%RA"
MJUK:S^1CA)*,YTD]+W7HQOB;_D5M5_Z])?\ T$UYY\$?^/;6/]^+^35Z'XF_
MY%;5?^O27_T$UYY\$?\ CVUC_?B_DU*E_NL_5#J_[U3]&>L4445PG>>+>*/^
M2WV/_7:V_D*]IKQ;Q1_R6^Q_Z[6W\A7M-=V*^"GZ'#A?CJ>IYQ/;P7GQGN;2
MYB66"?2MCHPX(KBM8TW5/AAXMBOK!F>RD)\EF^[(G>-_<?X&NW+8^.H'][3L
M?IG^E=IKFBV?B#29M.OH]T4@X(ZHW9A[BM%7]DXJ6L7%77WF3H>U4G'22D[/
M[AGA_7K+Q'I$6H63Y1^'0_>C;NIK4KP"QN]6^%OBY[>Y5I+20CS%'W9X\\.O
M^T/\17NVGW]MJEA#>V<JRV\RAD8>G^-<^)H>S?-'6+V.C#5_:+EEI);G Z:
M/CIJF!C-AD_^0Z]'KSRR4#XYZA@==-!/_CE>ATL1O'T16'VEZL****YCI"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1:?Y4QSF2*9T8\^H-=:JA5"CH!@52T?_ )!</X_S-7J;G*7Q.Y*A&/PJP4A
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#/;BMSPU8S+?ZUJ\T;1G4KH-$CC#>4B!%)';."<>XH Z"1UBC:1V"HH+,3V
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M6?;6%W9:U=SQ+$UI<D,5+D,&[GI]:8AUM_R,M]_UPB_FU+KRJF@7*HH50!@
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M-W'##)')&J*#*5/'X>]6;F*XGTJ6+$?VB2(J><*"1ZT 00VWVZQN)G)5[Q"
M?[J8^4?U^IIFE7SO)]@O8A'>P+^#KTW+5F*.ZBTE(E$8N8XPH^;*DCWQ3$MY
MKC4(KN>)8?)1E50VXDMC.3Z<4 :%%%%,04444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!$+:!9VG6&,3,,-(%&X_4U+110 4444 %->-) !(BN 0PW#.".].HH *
M*** $=%=2KJ&4\$$9!I:** "BBB@ HHHH **** "BBB@ HHHH **:7175"RA
MFSM!/)QZ5R/B/Q+J$6D>(_L-M<64^EQJ\=U-$&CFR,G;GK0!V%%9?AN>>Z\,
M:5<W,AEGFM(I)'(^\S*"3^M:E !1110 457OC,+"X-O((IA&Q1V7<%..#CO7
M.?#K5+_6O!T&H:E<>?<RRR[FV@<!R  !VXH ZNBBN.CU;5#\5WT=[L'3ETXW
M*PB,##;E7D]3W_.@#L:*S-%U=]7CNG?3[JS\BX> "X7!D"_Q#V-:= !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4W[-;_\ /"+_ +X%2T4 1BWA7I#&/HHIX51T 'T%+10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 5Y;B2.0JMK*X'\2XP?UIGVN7_GRG_3_ !JW10!4^UR_
M\^4_Z?XT?:Y?^?*?]/\ &K=% RI]KE_Y\I_T_P :/M<O_/E/^G^-6Z* *GVN
M7_GRG_3_ !H^UR_\^4_Z?XU;HH J?:Y?^?*?]/\ &C[7+_SY3_I_C5NB@"I]
MKE_Y\I_T_P :/M<O_/E/^G^-6Z* *GVN7_GRG_3_ !H^UR_\^4_Z?XU;HH J
M?:Y?^?*?]/\ &C[7+_SY3_I_C5NB@"I]KE_Y\I_T_P :/M<O_/E/^G^-6Z*
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M/M<O_/E/^G^-6Z* *GVN7_GRG_3_ !H^UR_\^4_Z?XU;HH J?:Y?^?*?]/\
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M?:Y?^?*?]/\ &C[7+_SY3_I_C5NB@"I]KE_Y\I_T_P :/M<O_/E/^G^-6Z*
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M/M<O_/E/^G^-6Z* *GVN7_GRG_3_ !H^UR_\^4_Z?XU;HH J?:Y?^?*?]/\
M&C[7+_SY3_I_C5NB@"I]KE_Y\I_T_P :/M<O_/E/^G^-6Z* *GVN7_GRG_3_
M !H^UR_\^4_Z?XU;HH J?:Y?^?*?]/\ &C[7+_SY3_I_C5NB@"I]KE_Y\I_T
M_P :/M<O_/E/^G^-6Z* *GVN7_GRG_3_ !H^UR_\^4_Z?XU;HH J?:Y?^?*?
M]/\ &C[7+_SY3_I_C5NB@"I]KE_Y\I_T_P :/M<O_/E/^G^-6Z* *GVN7_GR
MG_3_ !H^UR_\^4_Z?XU;HH J?:Y?^?*?]/\ &C[7+_SY3_I_C5NB@"I]KE_Y
M\I_T_P :/M<O_/E/^G^-6Z* *GVN7_GRG_3_ !H^UR_\^4_Z?XU;HH J?:Y?
M^?*?]/\ &C[7+_SY3_I_C5NB@"I]KE_Y\I_T_P :/M<O_/E/^G^-6Z* *GVN
M7_GRG_3_ !H^UR_\^4_Z?XU;HH J?:Y?^?*?]/\ &C[7+_SY3_I_C5NB@"I]
MKE_Y\I_T_P :/M<O_/E/^G^-6Z* *GVN7_GRG_3_ !H^UR_\^4_Z?XU;HH J
I?:Y?^?*?]/\ &C[7+_SY3_I_C5NB@"*&5I5):)X\'HV.?RJ6BB@1_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex5-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !N ]X# 2(  A$! Q$!_\0
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M>:C8B>\T]K)R>(V<,<>O%:-5[J]M;&+S;NXC@CZ;I&"C]:I_\)'HG_06LO\
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MPK%(JXWN37,_:4Z4H2[HZ%[.I5C./9G5T445QG:>1?&[_F$?]M/Z5V.F>+]
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M/PKP?Q%"GACX@2W6FQ%+6TF0_+T!(SBOH4]*\TN=%3Q'IWB6%8P9Q,KQG_:
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ME'\3>21)4#QL&4C((-)*P6)V)Q@'FL/PYX87PXC1Q:A=W$6,*DS A?I4NO\
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MUGTV1ROC_6!9:.-/AD"W=\PB09Y4'J:J6GPQTA+6,&>YW%06VR$ GOT--O\
MX7VFIW@NKS6=1EF!RK,PX^G%==I6G/IM@MLUY/=%1@23$;J'45.FE3EKU$J;
MJ5&ZL=.AXOXQT1/ _B;3[_3W8QY#$NV2#GG]*]JTO4(=4TVWO+=PT<J!@:Y;
M5/AO8:S?/=:A?WD[M]T,PPH]!5OP_P""(_#EPKVFJWS0#K [ H?TJZU2G4IJ
M\O>7D11IU*=25H^Z_,=\0I4B\%:@78#*@#/UK&^#[K_PASKN&?M+\9^E:.N^
M (O$-P\E[J]^8F;*PAAM7V'%4['X86VF*19:UJ4 /9&'^%$94O8>S<M6[[#E
M&K[?VBCI:VYT^O:Y;:'IKW,KJ9#\L29Y=CT%6[*XDFTV"XN5$4CQAG7/"G%<
MI%\.+/\ M&WO+O4[Z[:!MZI,P*YK<U_0#KT"P?VC=6D8R&6 @;_K6#5+1)^K
ML;IU=9->BN>3^ Y8Q\6;UMZ[6:?!SUYKW&O.H/A#I=M<">'4[])0<APPS_*N
MWL]/DM=+%FU[/,X! G<C?6N*G3J24H/R,<+"I3BXS7GN<EXROTMO%WAV)V 5
MYN>>G-=Q)''/"T;JKQN,$'D$5PU]\+K+4KLW5[J^H33=F9A\OTXKJ]&TLZ18
M):&[GN0G1YB"<5%5T^2*B]5Y%TE4YY.2T?F>.^-/"-YX/U+^V-'=UM68G*_\
MLR>WTKO?A:2W@^)CR2Y)KK[VS@U"TDM;F-9(9%VLI[BJ6A:';>'[#[':ES$&
MR-W:M*F)]I1Y);D4\-[.MSQV-2CI16;K6E2:O:"W2_N+,9^9H" 6'IS7&DF]
M3LDVEHCB/%&HPZ]X[TGP_'*IBA<RRG/!(YQ^E>D#@ "O/$^$6F1W(N4U34%G
M!SY@89S^5=SIUF]A9);O=2W)7_EI+C<:Z:[IN,5![>1S4%44I.:W\QFL6*ZE
MI%U:.H/FQLHSZXKQCX;ZP/#OBRXTJX?;#,YB)/\ >!P*]FU;3I-3M#!'?3V9
M/5X",D>G-<.WP=TAIC*=1OO,+;BVX9SZ]*TP]2G&G*%1[F>(IU)5(SIK8]&!
M!&0<BO/OC"R_\(>BY&XW*<?G75:+H4FCVKV_]IW=TI&%,Q!*?2L+4/AS:ZM.
M9=2U6_NN255V&%^G%947"%52;T7D:5E.=)Q2U?F.^%]Q'+X'LXD8;XMP8>G)
MJ_XUU^#1/#UPQD'VB12D* \LQK+TSX;6^C2L^G:SJ-N&/S*K#!_2M6V\%Z7'
M=K=W0>]N%^[).<X_"JFZ7M7.]UO:Q,%6]DH6L]KW.=^%GAF?2[*?5+V(QW-U
M]U3U"=:[^[94LYF8@ 1MDGZ5*    , =JP/$/A?_ (2$A9-4O+>#;M:*%@%;
MW-9RJ>UJ<TW8UC3]E3Y8*YYY\))4;Q1K+!AAD&WGK\U>N75Y;V5M)<7$JI'&
MI9B37"6GPFTZPE\VTU74(9/[R,!_2K5U\-H;Y=EYKFI31Y&49Q@_I717E1JU
M.;FT]#GH1K4J?)RZ^IT/A[5Y-;T][QHA'&TC"''\2=C7G7QL=,:0I()#.2OM
MQ7J-O81VFFQV-NS11QQ^6C+U KE;_P"&UCJTOFZEJ%Y=29X:1AP/3I6="I3A
M5YWHD77IU)TN1:MG0:(D5QX8L8V4-$]J@*^VT<5!>:IIWAJ.SLT7FXF$44*<
MGD]?I52U\'FPM?LUGK-_#%C "L./TJ"P\ VMKK4>J7&HWE[<1_=\]@0#ZU/[
MN[;EH7^\LDHZ]SJIY%AMY)'X55)->+_"R?/CS4E&-CK(W_CU>I>(/#YU^)86
MU&ZM8@"&2 @!_K7,67PHT_3KI;FSU74(9U_C5AG^5:4)TXTY1D]7Y&=>%252
M,HK1>9A_$32[KP]XCMO%&F(0"P\W;TW>_MBO0?#'B:R\2Z6ES;R#S ,21D\J
M:TYK&&ZL39W:_:(V7:WF#[U<C;_#/3K'4C>Z??WEH2<E(F&WZ4G4A4IJ,]&M
MF-4ZE.HY0U3W1V]17$?G6TL0_C0K^8IZ+M0*23@8R>].KC.P\"\.ZK)\/_&E
MS!?1.+:1MDAQSC/!%>PGQ?H LOM9U*#RL9SNI/$'A'2?$B#[= /,48$B_>%8
M6F_"K0=/N1,[3W(4Y"2M\HKOJ5:%9*4[J7YGGTZ5>BW&%G'\C*\0Z?<?$6T:
MZM83!9VJL8'=?FF;';VK*^'/C9=(=]"UE_*1&(C=OX3W!KV&**.&)8HD"(HP
M% X%<=KGPST37+QKIC+;2N<L82!DT4\13E%TJB]WIY!4P]2,E5IOWNOF=&^O
M:7'&KM?0A6Z?-UJ^CB1%=3E6&0?:N4T7X=Z)HTRS!9+F5#E6F;.#76]!@5R5
M%!/W'<[*;FU[ZL%>7?&>5/[(LXMXW^;G;FO3I4,D3('*$C 8=17$7OPQLM4N
MC<:CJE_=/S@2,,#]*UPTH0J*<WL98F,YTW""W+_PXD1_ FF!6!*QD, >AR:Z
MNN2T+P+#X>NUEL=5O5AW9:W+#8WZ5UM16<7-RB[W+HJ2@E)6:$9@JEB0 .2:
M\,T:ZA/QIDN-X\MKB3!^HKU_7=%?6[5;<:A<V:9^;R" 7'H<UQT?P>TF*83)
MJ5^L@.0P89S^5;X:=.$9<[W5MCGQ,*DY1Y%L[[GHU(2 "2<"J&D::^EV(MGO
M9[O!R))R"P'IQ4&NZ))K<*PC4KJS09W" @;_ *YKD2CS6OH=;<N6]M>QY/X,
M=?\ A<-Z=PVF2?!S[U[?7GD'PCTVVN1<P:IJ$<X.=X89S^5=U86KV=FD#W$E
MPR#'F2?>-=6+J0J-2@^ECFPM.=-.,UUN332I#"\DC!44$DD\"N$^&ERMY'K,
MH(.ZZ/?MS70^(_#7_"11+#)J5W;08(>.$@!_K6-H?PXM?#]ZES8ZK?)ALLFX
M;7]CQ40=-4I)O5^14U4=6+2T7F>?^+[>Z\'_ ! 6]TX;?M!WQJ.A[$?G7JN@
M:>-(\,E[EQY\J&6>1NY(JWJWAZPUFYM+B[CW26K[T/K['VIGB#P^-?LA:-?7
M%K%_$("!N'H:TG752,8O3NR(4'3E*2U[(\O^$%P%\3ZG$6 5HR5SW.ZO::\^
MMOA-IMC.D]IJ=_!,O\:,,_RKJY]&GGT=+#^U;M'48-PI&]OKQ2Q4Z=6IS1?X
M!A85*5/EDOQ.3\4-#XJ\66?AP3?Z-#F6X*'KZ"KC?#'1F0J9KK!&,&4_XU!:
M_"ZTL]1^WP:QJ*W6[<9-PR?TKLY[1YK VPN98V*[?.7&[ZT3K<JC&E+0(4>9
MRE5CJ>+^&+H>#/B-/ITD@%I*YCSGM_#7N(((R#D&N F^$ND7#-)+>WCSLVXR
MEANS73:)H#Z+:2VPU.[N4880S$$Q_2GB9TZMI1>O706&A4I7C):=-3GO'E^M
MKK?A]&8;7N1GGIR.:[AE2:(JP5T88(/((KA]0^&%GJMV;F^U?4)I/X2S#Y?I
MQ74:'I!T6P6T%Y/=*OW6F() ]*SJ.GR147JO(UIJISR<EH_,\D\;^#KKPMJ(
MUS16=8-^X[>L9_PKLOA0[2>%FD8Y9I"Q/J37;75K#>6TEO<1B2*1=K*>A%4-
M!T"U\/6;6MF6\IF+ -VK2>)]I1Y);F<,-[.MSQV,?Q'\0-,\-ZI%8W,4SNXR
M60<**Z>UNH;VUCN8'#Q2+N5AW%<)\3;/1[K3-LD(DU9_DMM@RV??VKJ/"FG2
MZ3X8L+&<YEBB ;Z]:SG"'LHR6C-(3G[647JC9KF/B!*D7@K4"[ ?(!^M=/7'
MZ]X!B\0W$DE[J]^8F;*PAAM7V'%9T7%33D[)%UE)P:BKMF9\'G7_ (0^1=PS
M]I?C/TKKM=URVT/37N974O\ =B3/+L>@KF+'X86NF BRUK48 >H1A_A4\?PX
MLSJ$%Y=ZG?7C0MO5)F!7-=%1T9U'-RT?D84U6A34%'7U.LT^>6YTZWGGC$<L
MD89T'\)/:O(/&\\;?%?3 '!V2Q;N>G->MZG8OJ%BUM'=S6A;_EK#C<!^-<1)
M\(M,FN3<RZI?O.3G>6&<_E2PTZ<).4G;<,3"I.*C%7V/0MZXSN&/7-8EOXB2
M]\3/I=HJRQ0QDSR@_=;L*R/^%?$PB(^(=4\L=MX_PK7\,^%K/PQ;316LDLK3
M-NDDE.68UE:E&+=[OT-5*K)I6LO4P/BTZKX.(9@"95 'KUJ]\.HXIO &F)(B
M. ARK 'N:BUWX>0>(;@RW^KW[IG*Q[AM7Z<5-H'@9/#L\;6>KWQA4Y,#,-C?
M7BMG.G[!4U+6]]C)0J>W=1QTM;<ZJ.&*$8BC1!Z*H%/HHKB.T**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT-V)LX\ORCFI+CQ;:6L9DN+2^B0?Q- 0* .@HK.N=9@MM/COC',\,BAAL3)
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M&MV"S1D"4<.G<&@"UJ-S=6MMYEI:?:7'5-^WBN=LO&%Y?W?V6WT=S,OWPTF
MOXXKKJYC05"^)-7P/XU_E0!TJ%BBEUVL1R,YQ3JP-0\76&F3F*ZBN4(/!,7!
M^E7M)UFWUF$S6R3",=&=, _2@#1HK$O?%%CI]TUO<1W"R#I^[^]]/6M*QO5O
MH/.2*6,9Z2KM- %FJUUJ%I9#-S<1Q>@9L$U9K/U;3K2^LY3<0)(50D$CD<4
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M]*@LK^ZNX1@W &Y0.,BN6UOP. TEYI,K12CYO+!P/PJ?P7KEW>&;3[XEIH.
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M,5W>CWRZCI5O<K_&O/UH H>,5!\+7Q(!PG'YU2\ @#P]P!_K#5[QA_R*M_\
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M:)MT#*)I2#U'I^= $OAJP,5O)?SH!<W;>8QQR!Z5NT@"HH'  % ((R""/:D
MM9^MN4T6\(Z^4P_2M"LKQ(Q30+L@X.PT ,T*&.X\,VT,JAD>( @_2N+U*QN_
M!NLK?6>YK-ST[?0UV_AS_D 6?_7,5=O;.&_M7M[A T;C!!H KZ1JUOK%BES
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9K)+;O YZQOC(_*IZ** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex5-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "I =P# 2(  A$! Q$!_\0
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MJ5SQ_P Q:RT74CS^O^>F*7]H1?1?B8O+7T:^:?\ F?J_L7T_4_XU5CN;:?\
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MJ,Y4 @$ELDL>?RP*W6;'UK:A04%=_<<&)Q+Q3UM;[]^_]?B.HHHKJ.<****
M"L'6-!T;7K2:QUS2]/U2PN  UM>60OE;CDD,K$=/X0 .F[FMZB@#X>^*/[+]
MO]FN]:^'GG"=6:[/ABX??%E<972&('DR<_ZMR1T =F.*^()H9[26X@GM_LT]
MK_H5Y:7??/\ G\Z_;IEQ]*_/[]JWP!!I&IV'CS2XD@BUIFL-:"# 34B28]8/
MHRQ[ WJP+9 .!YV(PZ:NOZ_K_(]7"8IWY7\N_H^^G6U][KJ?0_[-EIY/P?\
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M _%F SW]?:N=U;Q'HNCJ&OM4TZU4CAKN^LK$$9Z@RLN>AY(QQ7\S?@CX ?\
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M+P/XNT7Q&;)B,>5K*:+<SG2G^4A1.D3-@$?,<#S3]J3]L[]GG]CW0?!>N?M
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M?\$^?V#-/>._L?V-/V7+::VBC:TN_P#A1/PT,2.Q4$*/^$<4Y/S8!)&02 .
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MHH_B!*NDR X^6,_.F,?O"N.:^HR7A3AO,O#?B[C/%2XICG'#E;"T8T*4L/\
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MK_9:\3:O:VMKN%[JC:)X"XUDDX(_XD8R0.>"1M)K^VUUCCW")(5NA$S(HR0
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MHVB^(]4O=*;XI*HT8Z)XB8)L#.LK,P+*(<H,\-^X>$N'PN)X2\9,-B\R5/\
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MIK)N.N%*'%?"TI-3C'BBGPQ1_P!:81E]E3<I.*:Y8OEL[MW_ *2$G!4DPB-
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M$+_3? ?Q \_-S]K\'^*/M?VO_L":_P#7'K_G-?EG_P $9/\ @I4WPT\26W[
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MCQ+:3FUNK:%!JOAOQ#%'<)H7BO0YF8^3K?AN9H[NUE!Q\K( 8W9#]/2\0/\
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MZ_Q?[Q_I6'B.^;$\*R_FX!X3?G_NV(6OW?<>CX<*V'XI7;COBG_U)HGY'_\
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MOZ9!^SU^S;X2FEQK.N_'#5M;T^W'.[2=!\!ZYI6MMVPHE\0Z,JCUSZU])?\
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M)%_FA_X*=_&77_C7\,?^"/,7Q7U>$^+_ (MZR/C9X_L+TZ7IR>'O#/C?Q?\
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M[;3?5,_@'U/PQ_P[>_X+ ^+?AZ(%T3X8:_X\.BZ4H;.FI\,OCD?[<\$J2/\
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M?''PJGBI)+_57BS5VLG44XQ_]-SWMWO9V/[5$2&*,*&PI.<$#)(_'IVISE2
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M['? KQ*U?$8AO$XJ3<WJVW>3;25Y-ZMV22?IVN_H\/0PN%2PN%7*DGHMEO\
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MB-X9\0::",AM,U;1?%4%TC#LJ.!TW8(('Z26MA;V%G;V4"XM[>!8(%.,@*H
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MZZGUC1117HG"%%%% !1110  8X%<AXVUN#PKX4\0^(9\;=(TG4+W!]$0D?\
MCQ0_@1WKK=W&1WSC\ 3S^5?$O[4GQ#2VL8?AWIUP#<7*KJOB(A HL].4EM*T
MYMO :YEP2O("QHV<NP7FQ&S\E_F;8:@\5)16SWZZ=?T];V6IW'[)UG-#\-;B
M^N?]=JOB+5KQO7YBH'OW/KW]Z^GS]Q?K_C7C'P*TO^R?A-X)A?\ UL^GR:A_
MX/-4EUEQ]<3Y_#\:]G/W%^O^-&'V^7Z(K%N^(GZM?=='QO\ MA?\@'P3_P!A
MG6/_ $T-7P97W)^V)(%M_ $0//VKQ)<_]^_[#/?_ *Z'_)KX;K@Q/^]K_#^A
MZV#TP?\ V\_S/U)_9R_Y([X-_P"N6L?^GW6*]R/W%^O^-?/O[,]WYWPBT0?\
M^M[JUE^6JRC_ -GKZ"/W%^O^-=^'V^7Z(\G%?[Q/_$_RN2T445TG.,?H/K_0
MU\>?M>7\-OX.\,Z6#F6\\2?;U]FT3299&./I(H^OYU]AOT'U_H:_,7]I;QS#
MXM\='2;.?[3I'@^V?2&P,"^U-F)UI.#@^7&%CW# (0'C.*Y\3\*]'^ITY<O]
MK7DV_P /^"?/E?K)\(O#H\'?#;PII-V4@NETQK_5 "?^0GJ[?VM<DDX&Z-IG
M0@=< #)KX7_9_P#AK-XY\8VVJWT2CPSX8O#?:N&*C[=J0 _L72""5RD2DN^"
M#MX!W$9^U/C;IGQ%\0_#CQ1X9^&]OX>77_$>C:EHL>J:]JSZ?8Z&NKPRQMJK
M+%HEV]RR!W;8J@^8 VQY!NKGPNG*_3]#?,79_4_Y=_5K1?<V^^J\CY0\-^'O
MB1\:? /QNUFQ\'^"]:\+_'_5_%0T?5?$'C?6]-OE\+Z"B^!O K-HX\+^+HX]
MJ:$?$X(D1,.5(+,@'L'['?C6;QS\#O#&F^(X$3Q=\,-7U/X=^([6Z'S6&K^"
M7?0?0+N;0&3:3D$LY;KFO>_AAX:E\(_#[P=X5N+.PTZ;PYX=TK1#9Z7</>6$
M0T>** "%G5"<E-W=@SL,_*!7S]X(^%'Q-^&WQ\^*_C#PU:^$;SX6?%BZTK6K
MS2KKQ#JFG^([#Q7M4:UK)0>'YHS'*9-7ECA6X\QE:,"0."1T')>]UIIMT[_H
M;?@O_D[CXY?]DK^#?_IZ\?T[]J^RLM,_9F^)-IIEI!864%CHXM[.TMQ8(A'C
M#03\B@!5#-SD(H?<&QC@:?AKP/X[TK]H#XC_ !'O;3PR/!_C'P;X0\.Z6UKJ
M^K?\)%9CP;)KY+?V,_A\0GS'UUSB.=MI(V;\HKZO[0G@;Q7\1/A)XL\$^#X=
M#?6_$*Z;;*=<U-['3[0PZQ!J[/O31;II3A0 ODJ[ J.75S(!U7R_ X;]IRZ:
M30OA5X4N7\K2/B-\5_!/@[Q)>X0!O"\DC:_K6AE@"Q/B2/01;YR.$PP.%V_3
MLFEV$EB^E2VEJVE-:FS;3C;H;$V6W9Y1CV[  @P%Z #Y5SAZ\G^)/PO'Q?\
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MM''KL$BR,#AO,!(/RE0U>R>';F\O^#_3/!?VM-;AU#QKH&B0R[3I7A^:ZO%
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ME7C_ /\ *!_\T%'_  L+7_\ HE7C_P#\H'_S05ZO10'-_=7XGE'_  L+7_\
MHE7C_P#\H'_S04?\+"U__HE7C_\ \H'_ ,T%>KT4!S?W5^)Y1_PL+7_^B5>/
M_P#R@?\ S04?\+"U_P#Z)5X__P#*!_\ -!7J]% <W]U?B>4?\+"U_P#Z)5X_
M_P#*!_\ -!1_PL+7_P#HE7C_ /\ *!_\T%>KT4!S?W5^)Y1_PL+7_P#HE7C_
M /\ *!_\T%'_  L+7_\ HE7C_P#\H'_S05ZO10'-_=7XGE'_  L+7_\ HE7C
M_P#\H'_S04?\+"U__HE7C_\ \H'_ ,T%>KT4!S?W5^)Y1_PL+7_^B5>/_P#R
M@?\ S04?\+"U_P#Z)5X__P#*!_\ -!7J]% <W]U?B>4?\+"U_P#Z)5X__P#*
M!_\ -!1_PL+7_P#HE7C_ /\ *!_\T%>KT4!S?W5^)Y1_PL+7_P#HE7C_ /\
M*!_\T%'_  L+7_\ HE7C_P#\H'_S05ZO10'-_=7XGE'_  L+7_\ HE7C_P#\
MH'_S04?\+"U__HE7C_\ \H'_ ,T%>KT4!S?W5^)Y1_PL+7_^B5>/_P#R@?\
MS04?\+"U_P#Z)5X__P#*!_\ -!7J]% <W]U?B>4?\+"U_P#Z)5X__P#*!_\
M-!1_PL+7_P#HE7C_ /\ *!_\T%>KT4!S?W5^)Y1_PL+7_P#HE7C_ /\ *!_\
MT%'_  L+7_\ HE7C_P#\H'_S05ZO10'-_=7XGE'_  L+7_\ HE7C_P#\H'_S
M04?\+"U__HE7C_\ \H'_ ,T%>KT4!S?W5^)Y1_PL+7_^B5>/_P#R@?\ S04?
;\+"U_P#Z)5X__P#*!_\ -!7J]% <W]U?B?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !@ 7(# 2(  A$! Q$!_\0
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MU"502%K2V;G8O8GWKU8# Z5G6E!OW%8JFI+XA:***P-0HHHH **** "BBB@
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MFFTT%T244F15275=/@E,4MY D@ZJT@!_*DM=AERBLNZ\2:-8RB*ZU*VAD/\
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M.N2Y_P"6:^OUJQ\'=1M+CP-;VT<Z&>%B'3/(Y]*\[^..D7,'B>'4BK-;3Q!
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MK$&@9D:+<VT.JO:FUEMIV7.TON6NH%4+/1[2QE,D,?[P\%V.35\"A@+1110
.4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>brtx-20251006.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaaGmbP9z5Z8SekhvWB/bcna3yksNfs3ji5B1Jz2oRUL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:BRTX="http://biorestorativetherapiesinc.com/20251006" elementFormDefault="qualified" targetNamespace="http://biorestorativetherapiesinc.com/20251006">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://biorestorativetherapiesinc.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="brtx-20251006_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="brtx-20251006_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>brtx-20251006_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>brtx-20251006_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="brtx-20251006.xsd#Cover" roleURI="http://biorestorativetherapiesinc.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorativetherapiesinc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  06,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIORESTORATIVE
THERAPIES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001505497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">30-1341024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">40
    Marcus Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Melville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">760-8100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BRTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorativetherapiesinc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>brtx-20251006.xsd</File>
    <File>brtx-20251006_lab.xml</File>
    <File>brtx-20251006_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>21
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "BRTX",
   "nsuri": "http://biorestorativetherapiesinc.com/20251006",
   "dts": {
    "schema": {
     "local": [
      "brtx-20251006.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "brtx-20251006_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "brtx-20251006_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://biorestorativetherapiesinc.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-10-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-10-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://biorestorativetherapiesinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001493152-25-017446-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-017446-xbrl.zip
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M_#Z!UV4>RXXJXL_X("#V!#$$34!T4B.3@2  ?]=SPO8%SE&8LSQ%Q@\/L/B
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M-7BY''/J*QQWA9QV='<+JS>'!7]MPRW03ULMVGPD+'8@*+BW@.MZX"%UMS9
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M.2J=G6-(?KM\F0M#DM@&W__ Z;6BQC9CC_R<&(4@-<)<-BVOD]VPC9Z@(*S
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MW]3ZW4=$^M;"VE]OD1_?9\'T*.]',3KD+69;KF&7D[&6*'K0HL]:?1L53/\
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M"^ B=I+@/\LPH<LM5@NC*6+ ,(C.LUSB0D$9W\=)6'KS#/$;5[@$\DG>ZCO
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M8A@?(W7M1RCVS41*'P?*E0+T#_0LK6YID%S12&:E2OM>2CP?U8-":8B?7A\
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M>3NURFK*%%LTB_GRU_92*4?)<N*D%4S"/V1:#BD*5K@AO)H?\+52B)FXHLH
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M-KH 772X8GY<+'0X%4XAY.D<<KN^4VU\WJGNUCY^>C/J+AT.M/6X?_M,Q5S
M% \6"ZN^'*^+%C:GZB-EN?1CZ3%5+.R42:/6V-YLY&OVX#:7/:9CJ6C,)ZQ8
MZ(^8HA''*6>A7WU#FOA8*Q;.J?(333H*=/&&1+].> Q[?QF^):'/F9AP(5BY
M6,!)WZ2Z(?7Z[L?==='!)N ]A\!=&D!T*Q9H&) OL*I@8Q;NK8L"WN">_Q21
M?X/P-J(31J@?LX!037R9A)H)$DNR> :2I2.P3"@L-*$!A3DJ,J-D2-['(T;>
MB>![(O>/Y3BBX>R=,K]]*!,>PM@P!,"!0Z<\'A$<WF-#KF-+  !K3&,TOIC
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M\^T!4\I6LZDG)RS';Q0@"T"+LJFJRR0FR'[$C SP>0(8BP^IQ7Q(=,C"!/!
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ML[^QO;>].5JC(DG-M:E<BM(0+R0^F-!YGP?7 W" T@6!(B3(TSL4#?F4B<D
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MX.$'!RL'\- 9J0]YN> 4)W'EYHQ\P0#WE.0X-7AL,;_A"Y,R,T=$#WD@$&2
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M\>^^/=!*_P]02P$"% ,4    " !4B4A;1@DK*C,#   8#   $0
M    @ $     8G)T>"TR,#(U,3 P-BYX<V102P$"% ,4    " !4B4A;(/O6
M)/T*  !_A@  %0              @ %B P  8G)T>"TR,#(U,3 P-E]L86(N
M>&UL4$L! A0#%     @ 5(E(6Y A'B-H!P  ^%<  !4              ( !
MD@X  &)R='@M,C R-3$P,#9?<')E+GAM;%!+ 0(4 Q0    ( %2)2%N4AT<2
M0!4  -S,   *              "  2T6  !E>#$P+3$N:'1M4$L! A0#%
M  @ 5(E(6_?Y\[$S+@  .R,!  H              ( !E2L  &5X,3 M,BYH
M=&U02P$"% ,4    " !4B4A;%K^6]A,T   X5@$ "0              @ 'P
M60  97@T+3$N:'1M4$L! A0#%     @ 5(E(6R)1W1>S"@  :DH   D
M         ( !*HX  &5X-2TQ+FAT;5!+ 0(4 Q0    ( %2)2%OZV%I29Q
M %)"   *              "  029  !E>#DY+3$N:'1M4$L! A0#%     @
M5(E(6V88UH-6'@  ]N0   L              ( !DZD  &9O<FTX+6LN:'1M
64$L%!@     )  D % (  !+(      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="brtx-20251006.xsd" xlink:type="simple"/>
    <context id="AsOf2025-10-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2025-10-06</startDate>
            <endDate>2025-10-06</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-10-06" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-10-06" id="Fact000004">0001505497</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-10-06" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-10-06" id="Fact000010">2025-10-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-10-06" id="Fact000011">BIORESTORATIVE THERAPIES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-10-06" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-10-06" id="Fact000013">001-37603</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-10-06" id="Fact000014">30-1341024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-10-06" id="Fact000015">40     Marcus Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-10-06" id="Fact000016">Melville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-10-06" id="Fact000017">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-10-06" id="Fact000018">11747</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-10-06" id="Fact000019">(631)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-10-06" id="Fact000020">760-8100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-10-06" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-10-06" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-10-06" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-10-06" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-10-06" id="Fact000025">Common     Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-10-06" id="Fact000026">BRTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-10-06" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-10-06" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
